Search criteria | ||||
Real-world persistence of erenumab for preventive treatment of chronic and episodic migraine: Retrospective real-world study | ||||
Jonathan Gladstone 1, Sameer Chhibber 2, Jagdeep Minhas 3, Calum S Neish 3, G Sarah Power 3, Zhiyi Lan 3, Driss Rochdi 4, Jessica Lanthier-Martel 4, Natacha Bastien 4 | ||||
1Neurology, Cleveland Clinic Canada, Toronto, Ontario, Canada. 2Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada. 3Real-world Solutions, IQVIA, Kirkland, Québec, Canada. 4Neuroscience, Novartis Pharmaceuticals Canada Inc., Dorval, Québec, Canada. | ||||
Headache The Journal of Head and Face Pain PMID: 34807454 DOI: 10.1111/head.14218 |
||||
, Article | ||||
, Canada | ||||
Abstract: https://headachejournal.onlinelibrary.wiley.com/doi/10.1111/head.14218 | ||||
Condition | Year | Language | Analysis type | |
, Health status & patient reported outcomes | 2022 | English | , Clinical setting: Primary care, direct to patient research | |
Real-world 12-month Retention on Secukinumab Among Axial Spondyloarthritis Patients within the Canadaian Spondyloarthritis (CanSpA) Research Network | ||||
Dr. Robert Inman, Dr. Denis Choquette, Dr. Majed Khraishi, Dr. Dafna Gladman, Shamiza Hussein, Drew Neish, Patrick Leclerc | ||||
Robert Inman (Toronto Western Hospital, Toronto); Denis Choquette (Institut de Rhumatologie de Montréal, Montréal); Majed Khraishi (Department of Medicine, Memorial University of Newfoundland, St. John's); Dafna Gladman (Krembil Research Institute, Toronto Western Hospital, Toronto); Shamiza Hussein (Novartis, Montreal); Drew Neish (IQVIA, Montreal); Patrick Leclerc (Novartis Canada, Montreal) | ||||
, Poster | ||||
, Canada | ||||
Abstract: https://asm.rheum.ca/wp-content/uploads/2022/01/2022-Poster-Presentations.pdf | ||||
Condition | Year | Language | Analysis type | |
, Clinical practice | 2022 | English | , Clinical setting: hospital | |
Concomitant Medication Use in the Treatment Journey of Pulmonary Arterial Hypertension Patients: A Canadian Retrospective Claims Analysis | ||||
Essam Ibrahim1, Assem Al-Akabawi1, Moses Dawodu1, Juejing Ling2, Irene Wang2, Brad Millson3 | ||||
1Janssen Canada Inc, Toronto, ON, Canada; 2IQVIA Solutions Canada Inc., Mississauga, ON, Canada; 3IQVIA Solutions Canada Inc., Kanata, ON, Canada | ||||
, Poster | ||||
, Canada | ||||
Condition | Year | Language | Analysis type | |
, Endocrinology | 2022 | English | , Clinical setting: hospital, Clinical setting: Primary care, direct to patient research, Observational study | |
Real-World Drug Retention and Initiation of Combination Drug Therapy for Patients with Pulmonary Arterial Hypertension in Canada: A Retrospective Prescription Claims Database Study | ||||
Essam Ibrahim1, Assem Al-Akabawi1, Moses Dawodu1, Juejing Ling2, Jillian Murray2, Brad Millson3 | ||||
1Janssen Canada Inc, Toronto, ON, Canada; 2IQVIA Solutions Canada Inc., Mississauga, ON, Canada; 3IQVIA Solutions Canada Inc., Kanata, ON, Canada | ||||
IQVIA Canadian Private Drug Plan (PDP) databases |
||||
, Poster | ||||
, Canada | ||||
Condition | Year | Language | Analysis type | |
2022 | English | , direct to patient research | ||
A real-world, observational study of erenumab for migraine prevention in Canadian patients | ||||
Werner J Becker 1, Sian Spacey 2, Elizabeth Leroux 3, Rose Giammarco 4, Jonathan Gladstone 5, Suzanne Christie 6, Arash Akaberi 7, G Sarah Power 8, Jagdeep K Minhas 9, Johanna Mancini 7, Driss Rochdi 10, Ayca Filiz 10, Natacha Bastien 10 | ||||
1Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada. 2Division of Neurology, University of British Columbia, Vancouver, British Columbia, Canada. 3Brunswick Medical Center, Montreal, Quebec, Canada. 4Hamilton Headache Clinic, Hamilton, Ontario, Canada. 5Gladstone Headache Clinic, Toronto, Ontario, Canada. 6Ottawa Headache Centre Inc., Ottawa, Ontario, Canada. 7IQVIA Solutions Canada Inc., Montreal, Quebec, Canada. 8IQVIA Solutions Canada Inc., Mississauga, Ontario, Canada. 9IQVIA Solutions Canada Inc., Ottawa, Ontario, Canada. 10Novartis Canada, Dorval, Quebec, Canada. | ||||
Headache. 2022 Apr;62(4):522-529. doi: 10.1111/head.14291. Epub 2022 Apr 10. PMID: 35403223. |
||||
, Article | ||||
, Canada | ||||
Abstract: https://pubmed.ncbi.nlm.nih.gov/35403223/ | ||||
Condition | Year | Language | Analysis type | |
, Neurological disorders | 2022 | English | , Observational study | |
Characterisation of Pulmonary Arterial Hypertension (PAH) Patients Initiating a New PAH Specific Therapy in the Context of Age: Insights from EXPOSURE | ||||
P. Escribano (1), S. Gaine (2), P. Biedermann (3), A. Muller (3), M. Valge (4), T. Lange (5), S. Söderberg (6) | ||||
1 Pulmonary Hypertension Unit, Cardiology Department, CIBERCV, Hospital 12 de Octubre, Madrid, Spain 2 National Pulmonary Hypertension Unit, Mater Misericordiae University Hospital, Dublin, Ireland 3 Actelion Pharmaceuticals Ltd, Allschwil, Switzerland 4 StatFinn Estonia OÜ, Tartu, Estonia (now IQVIA) 5 University Medical Center Regensburg, Regensburg, Germany 6 Department of Public Health and Clinical Medicine, Cardiology and Heart Centre, Umeå University, Umeå, Sweden | ||||
JO - The Journal of Heart and Lung Transplantation VL - 40 IS - 4, Supplement SP - S109 PY - 2021 DA - 2021/04/01/ SN - 1053-2498 |
||||
, Abstract | ||||
, Canada, Europe | ||||
Abstract: https://www.jhltonline.org/article/S1053-2498(21)00365-X/fulltext#articleInformation | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease | 2021 | English | , Epidemiological study, Observational study | |
Risk Factors and Medical Resource Utilization of Respiratory Syncytial Virus, Human Metapneumovirus and Influenza Related Hospitalizations in Adults – A Global Study During the 2017-2019 Epidemic Seasons (Hospitalized Acute Respiratory Tract Infection [HARTI] Study) | ||||
Ann R Falsey, Edward E Walsh, Stacey House, Yannick Vandenijck, Xiaohui Ren, Sofia Keim, Diye Kang, Pascale Peeters, James Witek, Gabriela Ispas | ||||
University Of Rochester School Of Medicine and Rochester Regional Health, Rochester, NY, United States; Washington University School of Medicine, St Louis, MO, United States; Janssen Infectious Diseases, Beerse, Belgium; IQVIA Real-World Solutions, Courbevoie, France; Janssen Research & Development, LLC, Titusville, NJ, United States | ||||
, Article | ||||
, Argentina, Australia, Brazil, Canada, France, Germany, Japan, Korea, Malaysia, Mexico, South Africa, USA | ||||
Abstract: https://academic.oup.com/ofid/advance-article/doi/10.1093/ofid/ofab491/6381446 | ||||
Condition | Year | Language | Analysis type | |
, Infectious disease | 2021 | English | , Burden of illness, Clinical setting: hospital, Epidemiological study, Observational study, Patient questionnaire, Prospective study | |
Understanding the COVID Impact on Healthcare System in Canada | ||||
Juejing Ling, Scott Shi, Marc Lapierre, HuijuanYang, Brad Millson | ||||
Juejing Ling IQVIA, Scott Shi IQVIA, Marc Lapierre IQVIA, HuijuanYang IQVIA, Brad Millson IQVIA | ||||
2021 CADTH Symposium Confrence, November 2, 3 and 4, 2021 |
||||
, Poster | ||||
, Canada | ||||
Condition | Year | Language | Analysis type | |
, COVID-19 | 2021 | English | , Clinical setting: Primary care, Economic evaluation | |
Prescribing patterns among in-person vs virtual primary care visits pre-and post-COVID-19 in Ontario, Canada | ||||
Muratov S, Neish D, Ellis K, Wang I, Yang H, Bhattacharjee P, Barot P, Kukaswadia A | ||||
Muratov S, Neish D, Ellis K, Wang I, Yang H, Bhattacharjee P, Barot P, Kukaswadia A - all IQVIA authors | ||||
CAPT 2021 Confrence, October 25-27, 2021 |
||||
, Poster | ||||
, Canada | ||||
Condition | Year | Language | Analysis type | |
, COVID-19 | 2021 | English | , Clinical setting: Primary care, Public Health, Survey research | |
Real-world persistence of erenumab for preventive treatment of chronic and episodic migraine: Retrospective real-world study | ||||
Jonathan Gladstone 1, Sameer Chhibber 2, Jagdeep Minhas 3, Calum S Neish 3, G Sarah Power 3, Zhiyi Lan 3, Driss Rochdi 4, Jessica Lanthier-Martel 4, Natacha Bastien 4 | ||||
1Neurology, Cleveland Clinic Canada, Toronto, Ontario, Canada. 2Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada. 3Real-world Solutions, IQVIA, Kirkland, Québec, Canada. 4Neuroscience, Novartis Pharmaceuticals Canada Inc., Dorval, Québec, Canada. | ||||
PMID: 34807454 DOI: 10.1111/head.14218 |
||||
, Article, Book chapter | ||||
, Canada | ||||
Abstract: https://pubmed.ncbi.nlm.nih.gov/34807454/ | ||||
Condition | Year | Language | Analysis type | |
, Miscellaneous | 2021 | English | , direct to patient research, Retrospective cohort analysis | |
Real-world treatment patterns, healthcare resource use and clinical outcomes of patients receiving second line therapy for advanced or metastatic gastric cancer | ||||
Gomez-Ulloa D1, Amonkar M2, Kothari S3, Cheung WY4, Chau I5, Zalcberg J6, Lara N1, Falcone A7 | ||||
1 IQVIA, Barcelona, Spain 2 Merck & Co., Inc., North Wales, PA, US 3 Merck & Co., Inc., Kenilworth, NJ, US 4 British Columbia Cancer Agency, Vancouver, BC, Canada 5 Royal Marsden Hospital, London, UK 6 Alfred Health, Melbourne, Australia 7 University of Pisa, Pisa, Italy | ||||
BMC Gastroenterology BMC Gastroenterology volume 20, Article number: 133 (2020) |
||||
, Article | ||||
, Australia, Canada, Italy, UK | ||||
Abstract: https://doi.org/10.1186/s12876-020-01232-z | ||||
Condition | Year | Language | Analysis type | |
, Oncology | 2020 | English | , Retrospective cohort analysis | |
Patient preferences, treatment satisfaction, and quality of life in newly diagnosed and relapsed/refractory multiple myeloma patients receiving injectable-containing or fully oral therapies: the EASEMENT study | ||||
Neil Rabin1, Rami Kotb2, Athanasios Zomas3, Alonso Fernandez-Nistal3, Rocco D’Ambrosio3, Nawal Bent-Ennakhil3, Montserrat Roset4, Ombretta Annibali5 | ||||
1 University College London Hospitals, London, and North Middlesex University Hospital, UK; 2 CancerCare Manitoba, Winnipeg, Manitoba, Canada; 3 Takeda Pharmaceuticals International AG, Zurich, Switzerland; 4 IQVIA, Barcelona, Spain; 5 Università Campus Bio-Medico di Roma, Rome, Italy | ||||
COMy (the 6th World Congress on Controversies in Multiple Myeloma), Virtual congress, 3-4 October 2020 |
||||
, Poster | ||||
, Canada, Italy, UK | ||||
Condition | Year | Language | Analysis type | |
, Hematology, Oncology | 2020 | English | , Population Based Study | |
Quantifying the burden of the treatment-resistant depression in Ontario: Shredding light on an inportant mental health issue | ||||
Brad Millson, G Sarah Power, Dr. Roger S. McIntyre | ||||
Brad Millson, G Sarah Power, IQVIA RWE team | ||||
CADTH 2020 |
||||
, Article | ||||
, Canada | ||||
Abstract: hhttps://www.sciencedirect.com/science/article/pii/S0165032720324903 | ||||
Condition | Year | Language | Analysis type | |
, Health status & patient reported outcomes, Mental health | 2020 | English | , Retrospective cohort analysis | |
A Retrospective Observational Cohort study to Assess the Prevalence of Diabetic Kidney Disease Among Type 2 Diabetes Patients in Ontario, Canada | ||||
Wally Rapattoni, David Zante, Ali Tehrani, Varun Myageri, Shane Golden, Brad Millson, Sheldon W. Tobe, Jennifer B. Rose | ||||
Ali Tehrai, Varun Myageri, shane Golden, Brad Millson | ||||
ERA - EDRA Virtual Congress June 6-9 2020 |
||||
, Poster | ||||
, Canada | ||||
Abstract: https://academic.oup.com/ndt/article/35/Supplement_3/gfaa142.P0775/5853053 | ||||
Condition | Year | Language | Analysis type | |
, Diabetes, Public Health | 2020 | English | , Clinical setting: hospital, Clinical setting: Primary care, Cost analysis, direct-to-patient research, Observational study, Retrospective cohort analysis | |
Investigation of factors considered in the health technology assessment conducted by regulatory authority in eight countries | ||||
Akira Yuasa 1, Naohiro Yonemoto 1, Sven Demiya 2, Chihiro Foellscher 2, Shunya Ikeda 3 (rwesheorj 2) | ||||
1) Pfizer Japan Inc., Tokyo, Japan 2) IQVIA Solutions Japan, Tokyo, Japan 3) Graduate School of Medicine, International University of Health and Welfare, Tokyo, Japan | ||||
ISPOR 2020 Conference |
||||
, Abstract | ||||
, Australia, Canada, France, Germany, Italy, Japan, Spain, UK | ||||
Abstract: https://www.ispor.org/heor-resources/presentations-database/presentation/intl2020-3182/101019 | ||||
Condition | Year | Language | Analysis type | |
2020 | English | |||
GLP-1 RA Treatment and Dosing Patterns Among Type 2 Diabetes Patients in Six Countries: A Retrospective Analysis of Pharmacy Claims Data. | ||||
Divino V, Boye KS, Lebrec J, DeKoven M, Norrbacka K | ||||
IQVIA, Eli Lilly | ||||
Journal. Diabetes Ther. 2019 Jun;10(3):1067-1088. |
||||
, Article | ||||
, Belgium, Canada, France, Germany, Italy, Netherlands | ||||
Abstract: https://www.ncbi.nlm.nih.gov/pubmed/31028689 | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2019 | English | , Retrospective database analysis | |
A population-based analysis of anti-diabetic medications in four Canadian provinces: secular trends and prescribing patterns | ||||
Secrest MH, Azoulay L, Dahl M, Clemens KK, Durand M, Hu N, Targownik L, Turin TC, Dormuth CR, and Filion KB | ||||
IQVIA, Cambridge, MA | ||||
Pharmacoepidemiology & Drug Safety (in press) |
||||
, Article, In press/to be published | ||||
, Canada | ||||
Condition | Year | Language | Analysis type | |
, Diabetes, Drug Utlization Study | 2019 | English | , Epidemiological study, Observational study, Retrospective cohort analysis, Retrospective database analysis | |
The Pharmacoepidemiology of Anti-Depressant Prescribing Trends in Canadian Children from 2012 to 2016 | ||||
Aysha Lukmanji1BA&Sc, Tamara Pringsheim2,3MD, Andrew G. Bulloch1,3PhD, David G Stewart1, Parco Chan1, Ali Tehrani1, Scott B. Patten1,3,4MD PhD | ||||
1Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW Calgary, Alberta T2N 4Z6, Canada 2 Department of Clinical Neurosciences 3 Mathison Center for Research & Education, Hotchkiss Brain Institute, University of Calgary 4Cuthbertson & Fischer Chair in Pediatric Mental Health, University of Calgary. 5 IQVIA Canada | ||||
J Child Adolesc Psychopharmacol. 2019 Jul 29. doi: 10.1089/cap.2019.0018 |
||||
, Article | ||||
, Canada | ||||
Abstract: https://www.ncbi.nlm.nih.gov/pubmed/31355670 | ||||
Condition | Year | Language | Analysis type | |
2019 | English | |||
PRODUCTIVITY LOSS IN THE FIRST YEAR AFTER A CARDIOVASCULAR EVENT IN CANADA: A CROSS SECTIONAL STUDY OF WORKING ADULTS | ||||
A. Shekhar Pandey, B.Sc., MD, FRCPC, ABIM, CBNC;1 Milan Gupta, MD, FRCPC, FACC;1 Theodore Wein, MD, FRCPC, FAHA;2 Aren Fischer, MSc;3 Johanna Mancini, BSc, MSc, PhD;3 Eduard Sidelnikov, MD, PhD;4 Raina Rogoza, MSc;5 Louisa Pericleous, MSc, PhD.5 | ||||
1Department of Medicine, McMaster University, Hamilton, ON, Canada; 2Department of Neurology and Neurosurgery, McGill University, Montreal, QC, Canada; 3IQVIA, Mississauga, ON, Canada; 4AMGEN, Europe GmbH, Rotkreuz, Switzerland; 5AMGEN; Mississauga, ON, Canada. | ||||
, Poster | ||||
, Canada | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease | 2019 | English | ||
Trends in Psychotropic Medication Use for Canadian Children and Youth with ASD from 2010 to 2016: A Pharmacoepidemiologic Study | ||||
McMorris, C.A.1, Patten, S.2, Stewart, D.3, Tehrani, A.3 & Pringsheim, T.2 | ||||
1 Werklund School of Education, University of Calgary (Calgary, AB Canada) 2 Cumming School of Medicine, University of Calgary (Calgary, AB Canada) | ||||
, Poster | ||||
, Canada | ||||
Condition | Year | Language | Analysis type | |
, Mental health | 2019 | English | , Database Study | |
Prescriptions for Alpha Agonists and Antipsychotics in Children and Youth with Tic Disorders: A Pharmacoepidemiologic Study | ||||
Nicholas Cothros1, Davide Martino1, Carly McMorris2,3, David Stewart4, Ali Tehrani4 & Tamara Pringsheim1,5,6* | ||||
1Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary and Hotchkiss Brain Institute, Foothills Hospital, Calgary, AB, CA, 2Werklund School of Education, Alberta Childrens Hospital Research Institute (ACHRI), University of Calgary, Calgary, AB, CA, 3The Owerko Centre, Child Development Centre (CDC), Calgary, AB, CA, 4IQVIA, Kanata, ON, CA, 5Department of Psychiatry, Cumming School of Medicine, University of Calgary, Foothills Hospital, Calgary, AB, CA, 6Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, AB, CA | ||||
Tremor Other Hyperkinet Mov (N Y)v.9; 2019 |
||||
, Article | ||||
, Canada | ||||
Abstract: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691607/ | ||||
Condition | Year | Language | Analysis type | |
, Mental health | 2019 | English | , Survey research | |
LANDSCAPE TRANSFORMATION: pCPA CHANGES AND IMPACT TO MARKET ACCESS IN CANADA RESULTS FROM AN OBSERVATIONAL CROSS-SECTIONAL STUDY | ||||
Minhas, Jagdeep, M.Biotech1; Iqbal-Khan, Sarah, MBA2; Laforty, Callahan, MSc2; Ling, Juejing, MSc2; Shi, Scott, PharmD2; Millson, Brad, MBS1 | ||||
1Health Access and Outcomes, IQVIA, 535 Legget Drive, Kanata, ON, K2K 3B8; 2Health Access and Outcomes, IQVIA, 6700 Century Avenue, Mississauga, ON, L5N 6A4 | ||||
CADTH Symposium 2019, Edmonton, AB, April 14-16, 2019 |
||||
, Poster | ||||
, Canada | ||||
Condition | Year | Language | Analysis type | |
2019 | English | |||
Anti-VEGF persistence and switching in nAMD: real world analysis from a Canadian claims database | ||||
Tina Maio-Twofoot 1, Alexandros Sagkriotis 2, Atif Kukaswadia 3, Franois Lebeau 1, Valerie Gregory 1 | ||||
1 Novartis Pharmaceuticals Canada Inc., 2 Novartis Pharma AG; 3 IQVIA | ||||
, Poster | ||||
, Canada | ||||
Condition | Year | Language | Analysis type | |
, Ophthalmology | 2019 | English | , Longitudinal study, Observational study, Retrospective database analysis | |
Real-World Clinical Effectiveness of Liraglutide 3.0 mg for Weight Management in Canada | ||||
Sean Wharton1, Aiden Liu2, Arash Pakseresht2, Emil N?rtoft3, Christiane L. Haase3, Johanna Mancini4, G. Sarah Power5, Sarah Vanderlelie1, and Rebecca A. G. Christensen1 | ||||
1 Wharton Medical Clinic, Burlington, Canada. Correspondence: Sean Wharton (wharton@whartonmedicalclinic.com) 2 Novo Nordisk Canada Inc., Mississauga, Canada 3 Novo Nordisk A/S, S?borg, Denmark 4 IQVIA, Kirkland, Canada 5 IQVIA, Mississauga, Canada. | ||||
Obesity (Silver Spring). 2019 Jun;27(6):917-924. doi: 10.1002/oby.22462. Epub 2019 May 7. |
||||
, Article | ||||
, Canada, Nordic | ||||
Abstract: https://www.ncbi.nlm.nih.gov/pubmed/31062937 | ||||
Condition | Year | Language | Analysis type | |
, Obesity | 2019 | English | ||
Reduction in the Utilization of Prednisone or Methotrexate in Canadian Claims Data Following Initiation of Etanercept in Pediatric Patients with Juvenile Idiopathic Arthritis | ||||
Majed M M Khraishi1, Brad Millson2, John Woolcott3, Lisa Marshall4 and Heather Jones4 | ||||
1Memorial University of Newfoundland, St John's, NF, Canada, 2IQVIA, Kanata, ON, Canada, 3Global Outcomes & Evidence, Pfizer, Collegeville, PA, 4Pfizer, Collegeville, PA | ||||
Annals of the Rheumatic Diseases 2018;77:494. |
||||
, Article | ||||
, Canada | ||||
Abstract: https://acrabstracts.org/abstract/reduction-in-the-utilization-of-prednisone-and-or-methotrexate-following-the-initiation-of-etanercept-in-pediatric-patients/ | ||||
Condition | Year | Language | Analysis type | |
, Pediatrics, Rheumatology | 2019 | English | , Longitudinal study, Retrospective database analysis | |
Real-world utilization of methotrexate or prednisone co-therapy with etanercept among Canadian patients with rheumatoid arthritis: a retrospective cohort study | ||||
Majed Khraishi, Jelena Ivanovic, Yvonne Zhang, Brad Millson, Marie-Josee Brabant, John Woolcott, Heather Jones & Cinzia Curiale | ||||
Journal of Current Medical Research and Opinion, Accepted author version posted online: 25 Jun 2019, Published online: 10 Jul 2019 |
||||
, Article | ||||
, Canada | ||||
Abstract: ?https://doi.org/10.1080/03007995.2019.1636543 | ||||
Condition | Year | Language | Analysis type | |
, Rheumatology | 2019 | English | , Retrospective cohort analysis | |
AN EARLY LOOK AT THE SECOND DOSE COMPLETION OF THE RECOMBINANT ZOSTER VACCINE (RZV) IN CANADIAN ADULTS ? A RETROSPECTIVE ANALYSIS | ||||
Ashleigh McGirr1, Tara Bourgoin2, Michael Wortzman1, Brad Millson2, Shelly McNeil3 | ||||
1GSK, Mississauga, Canada, 2IQVIA, Ot tawa, Canada, 3Canadian Center for Vaccinology, IWK Heal th Centre and Nova Scotia Health Authority, Dalhousie University | ||||
The CIRN Annual Meeting, 20 & 21 November 2019 - Toronto, Canada |
||||
, Poster | ||||
, Canada | ||||
Abstract: https://gsk.envisionpharma.com/dv_gsk_bio/ | ||||
Condition | Year | Language | Analysis type | |
, Immunology and Vaccination | 2019 | English | , Retrospective database analysis | |
Patient characteristics and treatment patterns in multiple myeloma by treatment administration route and disease status: EASEMENT observational study | ||||
Rabin N1, Kotb R2, Zomas A3, Gonzalez F3, Fernandez-Nistal A3, D’Ambrosio R3, Bent-Ennakhil N3, Roset M4, Annibali O5 | ||||
1 University College Hospital, London, UK 2 Cancer Care Manitoba, Canada 3 Takeda Pharmaceuticals International AG, Switzerland 4 IQVIA, Barcelona, Spain 5 Università Campus Bio-Medico di Roma, Italy | ||||
IMW, Boston, US, 12-15 September 2019 |
||||
, Poster | ||||
, Canada, Italy, UK | ||||
Abstract: https://doi.org/10.1016/j.clml.2019.09.456 | ||||
Condition | Year | Language | Analysis type | |
, Clinical practice, Hematology | 2019 | English | , Epidemiological study, Observational study | |
The clinical and cost impact of switching to fingolimod versus other first line injectable disease-modifying therapies in patients with relapsing multiple sclerosis | ||||
Freedman MS1, Duquette P2, Grand'Maison F3, Lee L4, Vorobeychik G5, Lara N6, Khurana V7, Nakhaipour HR8, Schecter R8, Haddad P8 | ||||
1 University of Ottawa and The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada 2 Notre Dame Hospital, Université de Montréal, Montreal, Quebec , Canada 3 Neuro-Rive Sud Clinic , Greenfield Park , Quebec , Canada 4 Sunnybrook Health Sciences Centre , University of Toronto , Toronto , Ontario , Canada 5 Fraser Health Multiple Sclerosis Clinic Burnaby Hospital , Burnaby , British Columbia , Canada 6 IQVIA , Barcelona , Spain 7 Novartis Healthcare Private Limited , Hyderabad , India 8 Novartis Pharmaceuticals Canada Inc., Dorval, Quebec, Canada | ||||
Curr Med Res Opin. 2019 May;35(5):767-776 |
||||
, Article | ||||
, Canada | ||||
Abstract: doi: 10.1080/03007995.2019.1565818. Epub 2019 Jan 21. | ||||
Condition | Year | Language | Analysis type | |
, Neurological disorders | 2019 | English | , Burden of illness, Retrospective Field Study | |
Real-world treatment patterns and clinical outcomes in patients receiving second-line (2L) treatment for advanced or metastatic gastric cancer (GC) | ||||
Amonkar M1, Gomez-Ulloa D2, Smita Kothari1, Cheung WY3, Chau I4, Zalcberg JR5, Lara N2, Falcone A6 | ||||
1 Merck & Co., Inc., Kenilworth, NJ, USA 2 IQVIA, Barcelona, Spain 3 British Columbia Cancer Agency, Vancouver, BC, Canada 4 Royal Marsden Hospital, London, UK 5 Alfred Health, Melbourne, Australia 6 University of Pisa, Pisa, Italy | ||||
BMC Gastroenterology volume 20, Article number: 133 (2020) |
||||
, Poster | ||||
, Australia, Canada, Italy, UK | ||||
Condition | Year | Language | Analysis type | |
, Oncology | 2019 | English | , Retrospective cohort analysis | |
Severe, eosinophilic asthma in primary care in Canada: a longitudinal study of the clinical burden and economic impact based on linked electronic medical record data. | ||||
Husereau D1, Goodfield J2, Leigh R3, Borrelli R2, Cloutier M2, Gendron A4,5. | ||||
1Department of Epidemiology and Community Medicine, School of Epidemiology and Public Health, University of Ottawa, Room 101, 600 Peter Morand Crescent, Ottawa, ON K1G 5Z3 Canada 2IQVIA, Mississauga, ON Canada 3Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB Canada 4AstraZeneca Canada Inc, Mississauga, ON Canada 5Department of Medicine, University of Montreal, Montreal, QC Canada | ||||
Allergy Asthma Clin Immunol. 2018 Apr 24;14:15. |
||||
, Article | ||||
, Canada | ||||
Condition | Year | Language | Analysis type | |
2018 | English | , Retrospective database analysis | ||
Clinical characteristics of Glioblastoma Multiforme (GBM) Patients Who Reached 400 Days Post Diagnostic from a Retrospective Real-World Data | ||||
Mitrofan L.M.1,Krukas-Hampel M.R.2, Mendoza L.A.3 | ||||
1 IQVIA, Paris, FR; 2IQVIA New York, US; 3IQVIA, Prague, CZ | ||||
ESMO 2018 |
||||
, Poster | ||||
, Australia, Brazil, Canada, France, Germany, Italy, Mexico, Spain, Taiwan, UK | ||||
Condition | Year | Language | Analysis type | |
, Oncology | 2018 | English | ||
Clinical Characteristics of 3,030 Glioblastoma Multiforme (GBM) Patients in High, Upper Middle and Lower Middle Economic Regions Based on Real-World Data (RWD) | ||||
Mitrofan L1 , M.R. Krukas-Hampel M.R2 , L.A. Mendoza L.A3 | ||||
IQVIA, Paris, FR; IQVIA New York, US; IQVIA, Prague, CZ | ||||
ESMO 2018 |
||||
, Poster | ||||
, Australia, Brazil, Canada, France, Germany, Italy, Mexico, Spain, Taiwan, UK | ||||
Condition | Year | Language | Analysis type | |
, Oncology | 2018 | English | ||
Impact of the Adalimumab Patient Support Program's Care Coach Calls on Persistence and Adherence in Canada: An Observational Retrospective Cohort Study | ||||
John K. Marshall MD, MSc, FRCPC 1, Louis Bessette MD, MSc, FRCPC 2, Carter Thorne MD, FRCPC 3, Neil H. Shear MD, FRCPC 4, 5, Gerald Lebovic PhD 6, 7, Sebastien K. Gerega MBA 8, Brad Millson MBS 8, Driss Oraichi PhD 8, Tania Gaetano B.Comm, MIS 9, Sandra Gazel MBA, MSc 9, Martin G. Latour PhD 9, Marie-Claude Laliberté PhD 9 | ||||
1 Department of Medicine, Division of Gastroenterology, Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada 2 Department of Medicine, Laval University, Quebec City, Quebec, Canada 3 Southlake Regional Health Centre, Newmarket, Ontario, Canada 4 Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada 5 Department of Medicine, Division of Dermatology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada 6 Applied Health Research Centre, St. Michael's Hospital, Toronto, Ontario, Canada 7 Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada 8 QuintilesIMS, Kirkland, Quebec, Canada 9 AbbVie Corporation, St. Laurent, Quebec, Canada | ||||
Clinical Therapeutics, Volume 40, Issue 3 pages 415-429.e6 |
||||
, Canada | ||||
Abstract: https://www.sciencedirect.com/science/article/pii/S014929181830050X?via%3Dihub#! | ||||
Condition | Year | Language | Analysis type | |
, Miscellaneous | 2018 | English | , Observational study, Retrospective cohort analysis | |
Impact of the Adalimumab Patient Support Program on Clinical Outcomes in Ankylosing Spondylitis: Results from the COMPANION Study | ||||
Louis BessetteEmail author, Gerald Lebovic, Brad Millson, Katia Charland, Krishna Donepudi, Tania Gaetano, Valencia Remple, Martin G. Latour, Sandra Gazel, Marie-Claude Laliberté, Carter Thorne | ||||
1. Department of Medicine, Laval University, Quebec, Canada 2. Applied Health Research Centre, St. Michael’s Hospital, Toronto, Canada 3. Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada 4. QuintilesIMS, Quebec, Canada 5. AbbVie Corporation, Quebec, Canada 6. Southlake Regional Health Centre, Newmarket, Canada | ||||
Rheumatology and Therapy, June 2018, Volume 5, Issue 1, pages 75-85 |
||||
, Canada | ||||
Abstract: https://link.springer.com/article/10.1007/s40744-018-0109-3 | ||||
Condition | Year | Language | Analysis type | |
, Miscellaneous | 2018 | English | , Longitudinal study | |
Canada's Study of Adherence Outcomes in Patients Receiving Adalimumab: 3-year Results From the COMPANION Study | ||||
John K. Marshall MD, MSc, FRCPC 1, Louis Bessette MD, MSc, FRCPC 2, Neil H. Shear MD, FRCPC 3, 4, Gerald Lebovic PhD 5, 6, Jennifer Glass PhD 7, Brad Millson MBS 7, Tania Gaetano BComm, MIS 8, Sandra Gazel MBA, MSc 8, Martin G. Latour PhD 8, Marie-Claude Laliberté PhD 8, J. Carter Thorne MD, FRCP 5, 6 | ||||
1 Department of Medicine, Division of Gastroenterology, Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada 2 Department of Medicine, Laval University, Quebec City, Quebec, Canada 3 Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada 4 Department of Medicine, Division of Dermatology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada 5 Applied Health Research Centre, St. Michael's Hospital, Toronto, Ontario, Canada 6 Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada 7 QuintilesIMS, Health Access and Outcomes, Kirkland, Quebec, Canada 8 AbbVie Corporation, St. Laurent, Quebec, Canada | ||||
, Canada | ||||
Abstract: https://www.sciencedirect.com/science/article/pii/S014929181830184X?via%3Dihub | ||||
Condition | Year | Language | Analysis type | |
, Miscellaneous | 2018 | English | , Longitudinal study, Retrospective cohort analysis | |
Assessing the Benefits of Co-pay Card Usage Among Diabetic Patients in Canada | ||||
Jing Guo 1, Christian Silva 1, Chris Stewart 1, Andrew Leung 1, Behlool Khan 2, Johanna Mancini 2 | ||||
1 Department of Mechanical and Industrial Engineering, University of Toronto 2 IQVIA | ||||
, Poster | ||||
, Canada | ||||
Abstract: http://imsbrogancapabilities.com/pdf/rwe/frontiers-2018-final-poster-for-presentation.pdf | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2018 | English | , Retrospective cohort analysis | |
Cost-Effectiveness Analysis of Brodalumab in Moderate-to-Severe Plaque Psoriasis in Canada | ||||
Xue, W. 1, Gray, E. 1, Khoudigian-Sinani, S. 2, Barbeau, M. 3, Frieder, D. 3 | ||||
1 IQVIA, London, UK, 2 IQVIA Mississauga, ON, Canada, 3 Valeant Canada LP, Laval QC, Canada | ||||
ISPOR 23rd Annual International Meeting, May 19-23, 2018, Baltimore, MD, USA |
||||
, Poster | ||||
, Canada | ||||
Abstract: http://imsbrogancapabilities.com/pdf/rwe/valeantbrodalumab-cem-poster-ispor-final.pdf | ||||
Condition | Year | Language | Analysis type | |
, Dermatology | 2018 | English | , Database Study | |
Efficacy of Brodalumab in the Treatment of Moderate-to-Severe Psoriasis: A Network Meta-Analysis | ||||
Xue, W. 1, Saharia, P. 2, Gray, E. 1, Khoudigian-Sinani, S. 3, Barbeau, M. 4, Frieder, D. 4 | ||||
1. IQVIA, London, UK, 2. IQVIA Gurugram, India, 3. IQVIA Mississauga, ON, Canada, 4. Valeant Canada LP, Laval QC, Canada | ||||
, Poster | ||||
, Canada | ||||
Abstract: http://imsbrogancapabilities.com/pdf/rwe/valeantbrodalumab-nma-poster-ispor-final.pdf | ||||
Condition | Year | Language | Analysis type | |
, Dermatology | 2018 | English | , Meta analysis | |
pCPA CHANGES AND IMPACT TO MARKET ACCESS IN CANADA: RESULTS FROM AN OBSERVATIONAL CROSS-SECTIONAL STUDY | ||||
Minhas, Jagdeep, M.Biotech 1; Iqbal-Khan, Sarah, MBA 2; Laforty, Callahan, MSc 2; Millson, Brad, MBS 1 | ||||
1 1 Health Access and Outcomes, IQVIA, 535 Legget Drive, Kanata, ON, K2K 3B8 2 Health Access and Outcomes, IQVIA, 6755 Century Avenue, Mississauga, ON, L5N 6A4 | ||||
2018 CADTH Symposium, April 15-17, 2018, Halifax, NS, Canada |
||||
, Poster | ||||
, Canada | ||||
Abstract: http://imsbrogancapabilities.com/pdf/rwe/pcpa-changes-cadth-2018-poster-print.pdf | ||||
Condition | Year | Language | Analysis type | |
, Miscellaneous | 2018 | English | , Observational study | |
Potential Impact of Changes to Basket of Comparator Countries from PMPRB7 to PMPRB12 has on Canadian Product List Prices | ||||
van Doorn-Drennan, J. 1, Minhas, J. 1, Millson, B. 1, McCormick, J. 1 | ||||
1 IQVIA, Kanata, ON, Canada | ||||
ISPOR 23rd Annual International Meeting, May 19-23, 2018, Baltimore, MD, USA |
||||
, Canada | ||||
Abstract: http://imsbrogancapabilities.com/pdf/rwe/pmprb-ispor-poster-print.pdf | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2018 | English | ||
Real-World Clinical Effectiveness of Liraglutide 3.0 mg for Weight Management in Canada | ||||
1. Sean Wharton Wharton Medical Clinic, Burlington, ON, Canada 2. Aiden R Liu Novo Nordisk Canada, Mississauga, ON, Canada 3. Arash Pakseresht Novo Nordisk Canada, Mississauga, ON, Canada 4. Emil Nørtoft Novo Nordisk A/S, Copenhagen, Denmark 5. Christiane L Haase Novo Nordisk A/S, Copenhagen, Denmark 6. Johanna Mancini IQVIA, Montreal, QC, Canada 7. G Sarah Power IQVIA, Mississauga, ON, Canada 8. Sarah VanderLelie Wharton Medical Clinic, Burlington, ON, Canada 9. Rebecca AG Christensen Wharton Medical Clinic, Burlington, ON, Canada | ||||
1. Sean Wharton Wharton Medical Clinic, Burlington, ON, Canada 2. Aiden R Liu Novo Nordisk Canada, Mississauga, ON, Canada 3. Arash Pakseresht Novo Nordisk Canada, Mississauga, ON, Canada 4. Emil Nørtoft Novo Nordisk A/S, Copenhagen, Denmark 5. Christiane L Haase Novo Nordisk A/S, Copenhagen, Denmark 6. Johanna Mancini IQVIA, Montreal, QC, Canada 7. G Sarah Power IQVIA, Mississauga, ON, Canada 8. Sarah VanderLelie Wharton Medical Clinic, Burlington, ON, Canada 9. Rebecca AG Christensen Wharton Medical Clinic, Burlington, ON, Canada | ||||
ISPOR 23rd Annual International Meeting, May 19-23, 2018, Baltimore, MD, USA |
||||
, Poster | ||||
, Canada | ||||
Abstract: http://imsbrogancapabilities.com/pdf/rwe/nn-ispor-poster-may-2018.pdf | ||||
Condition | Year | Language | Analysis type | |
, Obesity | 2018 | English | , Retrospective cohort analysis | |
Longitudinal Study of Patient Profile and Treatment Patterns of Omalizumab in Patients with Asthma Refractory to Inhaled Medications | ||||
Jason K. Lee 1, Suvina Amin 2, Michelle Erdmann 2, Atif Kukaswadia 3, Jelena Ivanovic 3, Aren Fischer 3, Alain Gendron 2,4 | ||||
1 Evidence Based Medical Educator Inc. Toronto, On, Canada and Section Head of Asthma at Canadian Society of Allergy and Clinical Immunology; 2 AstraZeneca, Mississauga, ON, Canada; 3 IQVIA, Toronto, ON, Canada; 4 Department of medicine, University of Montreal, Montreal, Canada | ||||
, Poster | ||||
, Canada | ||||
Condition | Year | Language | Analysis type | |
, Respiratory disease | 2018 | English | , Longitudinal study, Retrospective cohort analysis | |
Persistence with Insulin Glargine 300 lU/mL compared to other Basal Insulins: A Canadian Retrospective Cohort Study | ||||
Kobina Quansah 1, Luc Sauriol 2, Atif Kukaswadia 1, Samantha Bremner 3, Bradley Millson 3 | ||||
1 IQVIA, Mississauga, ON, Canada, 2 Sanofi, Laval, QC, Canada, 3 IQVIA, Kanata, ON, Canada | ||||
ADA 2018, June 22-26, 2018, Orlando, FL |
||||
, Poster | ||||
, Canada | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2018 | English | , Retrospective cohort analysis | |
Identification of Incident Pancreatic Cancer in Administrative Health Data: A Validation Study by the Canadian Network for Observational Drug Effect Studies | ||||
Wu JW, Axzoulay L, Huang A, Paterson M, Wu F, Secrest MH, Filion K | ||||
Wu JW: Analysis Group; Secrest MH: IQVIA | ||||
34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management |
||||
, Abstract | ||||
, Canada | ||||
Condition | Year | Language | Analysis type | |
, Database Validity and methodology, Diabetes, Oncology | 2018 | English | , Database Study, Retrospective cohort analysis, Retrospective database analysis | |
TREATMENT AND DOSING PATTERNS AMONG PATIENTS WITH TYPE 2 DIABETES (T2D) INITIATING GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAS) IN SEVERAL COUNTRIES | ||||
Norrbacka K, Divino V, Boye K, Lebrec J, Dekoven M | ||||
Eli Lilly, IQVIA | ||||
ISPOR Europe 2018 |
||||
, Poster | ||||
, Belgium, Canada, France, Germany, Italy, Netherlands | ||||
Abstract: https://tools.ispor.org/ScientificPresentationsDatabase/Presentation/84796?pdfid=57383 | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2018 | English | , Retrospective database analysis | |
Canadian Study of Adherence Outcomes in HUMIRA® (Adalimumab) Patients – Three-Year Results from the COMPANION Study in Rheumatology Patients | ||||
Bessette L1, Millson B2, Sung M2, Gaetano T3, Latour M3, Laliberté MC3 | ||||
1 Department of Medicine, Laval University, Quebec City, Quebec, Canada 2 IMS Brogan, Kirkland, Quebec, Canada; 3AbbVie Corporation, St. Laurent, Quebec, Canada | ||||
Canadian Rheumatology Association 2017 Scientific Meeting, February 8-11, Ottawa, Canada |
||||
, Poster | ||||
, Canada | ||||
Abstract: http://www.imsbrogancapabilities.com/pdf/rwe/abbvie-cra-2017.pdf | ||||
Condition | Year | Language | Analysis type | |
, Rheumatology | 2017 | English | , Database Study | |
Impact of adalimumab’s patient support program on clinical outcomes in inflammatory bowel diseases: Results from the COMPANION study | ||||
Marshall JK1, Narula N1, Millson B2, Charland K2, Sung M2, Gaetano T3, McHugh K3, Latour M3, Laliberté MC3 | ||||
European Crohn’s and Colitis Organization 2017 Conference, February 15-18, Barcelona, Spain |
||||
, Poster | ||||
, Canada | ||||
Condition | Year | Language | Analysis type | |
, Gastrointestinal disorders | 2017 | English | , Retrospective database analysis | |
Prevalence of Primary Biliary Cholangitis in Canada: First National Study | ||||
Yoshida EM1, Thiele S2, Fischer A2, Mason A3, Shah H4, Peltekian K5, Hux M2, Borrelli R2 | ||||
1 Division of Gastroenterology, University of British Columbia 2 QuintilesIMS 3 University of Alberta 4 University of Toronto 5 Dalhousie University | ||||
CANADIAN DIGESTIVE DISEASES 2017 CONFERENCE, MARCH 3-6, BANFF, Canada |
||||
, Poster | ||||
, Canada | ||||
Abstract: http://www.imsbrogancapabilities.com/pdf/rwe/cddw-conference.pdf | ||||
Condition | Year | Language | Analysis type | |
, Miscellaneous | 2017 | English | , Retrospective cohort analysis | |
Canadian Study of Adherence Outcomes in HUMIRA® (Adalimumab) Patients: Three-Year Results from the COMPANION Study in Gastroenterology Patients | ||||
Marshall JK1, Millson B2, Sung M2, Gaetano T3, Latour M3, Laliberté MC3 | ||||
1 Department of Medicine, Division of Gastroenterology, Farncombe Family Digestive Health Research Institute; McMaster University, Hamilton, Ontario, Canada 2 IMS Brogan, Kirkland, Quebec, Canada 3 AbbVie Corporation, St. Laurent, Quebec, Canada | ||||
Canadian Digestive Diseases Week 2017 Annual Scientific Conference, March 3-6, Banff, Canada |
||||
, Poster | ||||
, Canada | ||||
Abstract: http://www.imsbrogancapabilities.com/pdf/rwe/cddw-abbvie.pdf | ||||
Condition | Year | Language | Analysis type | |
, Gastrointestinal disorders | 2017 | English | , Database Study | |
Privacy, Confidentiality, Security, and Ethics | ||||
L. Arbuckle, M. Chibba, K. El Emam, A. Cavoukian | ||||
Department of Pediatrics, Faculty of Medicine, University of Ottawa, 401 Smyth Road, Ottawa, Canada K1H 8L1 Electronic Health Information Laboratory, Children's Hospital of Eastern Ontario Research Institute, 401 Smyth Road, Ottawa, Ontario, Canada K1H 8L1 | ||||
Population Health Informatics, Jones & Bartlett Learning |
||||
, Book | ||||
, Canada | ||||
Condition | Year | Language | Analysis type | |
, Methodology | 2017 | English | , De-identification / anonymisation | |
HEALTH-ECONOMICS EVALUATIONS IN FRANCE, ENGLAND, CANADA AND AUTRALIA: COMPARISON OF METHODOLOGIES AND IMPACT ON DRUGS | ||||
Bucher D*, Abalan M-E*, Allou A*, Dumon L*, Vialard L *, Troubat A*, Maurel F* | ||||
IQVIA France - RWI | ||||
ISPOR 2017 |
||||
, Poster | ||||
, Australia, Canada, France, UK | ||||
Condition | Year | Language | Analysis type | |
, Comparative Effectiveness & Health Technology Assessment | 2017 | English | , Cost effectiveness, Literature Review, Pricing & Reimbursement, Review | |
SCHÉMAS THÉRAPEUTIQUES ET POSOLOGIQUES CHEZ DES PATIENTS AVEC UN DIABÈTE DE TYPE 2 (DT2) INITIANT UN TRAITEMENT PAR AGONISTE DU RÉCEPTEUR DU GLUCAGON-LIKE PEPTIDE 1 (AR GLP-1) EN EUROPE | ||||
Norrbacka K, Divino V, Dekoven M, Boye KS | ||||
Eli Lilly, IQVIA | ||||
Societé Francophone du Diabete 2017 |
||||
, Poster | ||||
, Belgium, Canada, France, Germany, Italy, Netherlands | ||||
Abstract: https://www.sfdiabete.org/sites/www.sfdiabete.org/files/files/evenements/17sfd_final_v12.pdf | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2017 | English | , Retrospective database analysis | |
UTILIZATION OF RADIUM-223 DICHLORIDE (RA-223) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN CANADA: A REAL-WORLD RETROSPECTIVE STUDY | ||||
Lapierre M, Fraelic A | ||||
IMS Health, Kirkland, QC, Canada, IMS Health, Canada, Kanata, QC, Canada | ||||
ISPOR 21st, May 21-25 - 2016 Washington DC USA Value in Health, 2016, 19(3): A162 |
||||
, Poster | ||||
, Canada | ||||
Abstract: http://www.valueinhealthjournal.com/article/S1098-3015(16)01560-6/abstract | ||||
Condition | Year | Language | Analysis type | |
, Oncology | 2016 | English | , Retrospective database analysis | |
REAL-WORLD COMPARISON OF METASTATIC MELANOMA TREATMENTS BETWEEN ACADEMIC AND COMMUNITY HOSPITALS IN CANADA: A RETROSPECTIVE STUDY | ||||
Lapierre M | ||||
IMS Health, Kirkland, QC, Canada | ||||
ISPOR 21st, May 21-25 - 2016 Washingtown DC USA |
||||
, Poster | ||||
, Canada | ||||
Abstract: http://www.imsbrogancapabilities.com/pdf/rwe/metastatic-melanoma-ispor-poster-2016.pdf | ||||
Condition | Year | Language | Analysis type | |
, Oncology | 2016 | English | , Retrospective database analysis | |
CHARACTERIZATION OF STATIN EFFECTIVENESS USING REAL-WORLD DATA IN A CANADIAN POPULATION | ||||
Shojaie S, McCurdy S, Thiele S, Ching Chau L, Martin L, Charland K, Dobson-Belaire W, Duclos M, Borrelli R | ||||
IMS Health Brogan., Mississauga, ON, Canada, IMS health Brogan, Kirkland, QC, Canada, IMS Health Brogan, Mississauga, ON, Canada | ||||
ISPOR 21st, May 2016, Washington, DC USA |
||||
, Poster | ||||
, Canada | ||||
Abstract: http://www.imsbrogancapabilities.com/pdf/rwe/statin-ispor-poster-2016.pdf | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease | 2016 | English | , Retrospective database analysis | |
Second-line drug regimens in metastatic melanoma patients based on BRAF mutation status: A Canadian real-world retrospective study | ||||
Bremner S1, Lapierre M2, Fraelic A1, Stewart D1 | ||||
1 IMS Health, Kanata, ON, Canada 2 IMS Health, Kirkland, QC, Canada | ||||
2016 ASCO Annual Meeting |
||||
, Abstract | ||||
, Canada | ||||
Abstract: http://meetinglibrary.asco.org/content/168312-176 | ||||
Condition | Year | Language | Analysis type | |
, Oncology | 2016 | English | , Retrospective database analysis | |
No Substitution: Not just for Physicians Anymore | ||||
Gillman A, Fischer A | ||||
QuintilesIMS, Toronto, Canada | ||||
2016 Annual CAPT Conference |
||||
, Poster | ||||
, Canada | ||||
Abstract: http://www.imsbrogancapabilities.com/pdf/rwe/capt-poster-2016.pdf | ||||
Condition | Year | Language | Analysis type | |
, Miscellaneous | 2016 | English | , Review | |
pCPA/CDR/pCODR Changes and Impact to Market Access in Canada | ||||
Millson B, Zhang Y | ||||
IMS Brogan, A unit of IMS Health, Kirkland, QC, Canada | ||||
2016 ISPOR Conference |
||||
, Poster | ||||
, Canada | ||||
Abstract: http://www.imsbrogancapabilities.com/pdf/rwe/hta-ispor-poster-2016.pdf | ||||
Condition | Year | Language | Analysis type | |
, Pricing and reimbursement | 2016 | English | , Database Study | |
Excess Healthcare Resource Utilization in Obesity Pharmacotherapy Candidates in Canada | ||||
Feroz T1, Charland K2, Heembrock S2, Borrelli R2, Skovgaard R1 | ||||
1 NovoNordisk Canada Inc. Canada 2 IMS Brogan Canada | ||||
13th International Conference on Obesity, 2016, May 1-4, Vancouver, Canada |
||||
, Poster | ||||
, Canada | ||||
Abstract: http://www.imsbrogancapabilities.com/pdf/rwe/obesity-conference-poster-2016.pdf | ||||
Condition | Year | Language | Analysis type | |
, Drug Utlization Study, Obesity | 2016 | English | , Retrospective cohort analysis | |
Estimating Canadian Heart Failure Prevalence Using Prescription Treatment Patterns | ||||
Jobin Gervais K1, Zaour N1, Caron J2, Borrelli R2, Fischer A2 | ||||
1 Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada 2 IMS Brogan, Mississauga, ON, Canada | ||||
, Poster | ||||
, Canada | ||||
Abstract: http://www.imsbrogancapabilities.com/pdf/rwe/novartis-heart-failure-poster-2016.pdf | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease | 2016 | English | , Retrospective cohort analysis | |
Characteristics of Patients with Mild to Severe Asthma in Canada | ||||
Gerega S1, Millson B1, Charland K1, Barakat S2, Sun X3, Jimenez R2, Waserman S4, FitzGerald JM5 | ||||
1 IMS Brogan, Kirkland, Québec, Canada 2 Teva Pharmaceutical Industries, Montréal, Québec, Canada 3 Teva Pharmaceutical Industries, Frazer, Pennsylvania, United States 4 McMaster University, Hamilton, Ontario, Canada 5 The Lung Centre, Vancouver, British Columbia, Canada | ||||
Canadian Society of Allergy and Clinical Immunology (CSACI), 2016, Sept. 29 - Oct. 2, Montréal, Canada |
||||
, Poster | ||||
, Canada | ||||
Abstract: http://www.imsbrogancapabilities.com/pdf/rwe/teva-poster.pdf | ||||
Condition | Year | Language | Analysis type | |
, Respiratory disease | 2016 | English | , Database Study, Retrospective database analysis | |
Canadian Study of Outcomes in HUMIRA® (Adalimumab) Patients with Support for Adherence - Dermatology Results from the COMPANION Study | ||||
Shear N1,2, Bessette L3, Marshall JK4, Lebovic G5,6, Gerega S7, Millson B7, Gaetano T8, Gazel S8, Latour M8, Laliberté MC8 | ||||
1 Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada 2 Department of Medicine, Division of Dermatology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada 3 Department of Medicine, Laval University, Quebec City, Quebec, Canada; 4Department of Medicine, Division of Gastroenterology, Farncombe Family Digestive Health Research Institute; McMaster University, Hamilton, Ontario, Canada 5 Applied Health Research Centre, St. Michael’s Hospital, Toronto, Ontario, Canada 6 Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada 7 IMS Brogan, Kirkland, Quebec, Canada 8 AbbVie Corporation, St. Laurent, Quebec, Canada | ||||
Dermatology Update 2016 Annual Meeting, November 3-6, Montreal, Canada |
||||
, Poster | ||||
, Canada | ||||
Abstract: http://www.imsbrogancapabilities.com/pdf/rwe/abbvie-dermatology-poster-2016.pdf | ||||
Condition | Year | Language | Analysis type | |
, Dermatology, Medication compliance | 2016 | English | , Database Study | |
Canadian Study of Outcomes in HUMIRA® (Adalimumab) Patients with Support for Adherence - Results from the COMPANION Study | ||||
Latour M1, Gerega S2, Millson B2, Bessette L3, Marshall JK4, Lebovic G5,6, Sung M2, Oraichi D2, Gaetano T1, Gazel S1, Laliberté MC1 | ||||
1 AbbVie Corporation, St. Laurent, Quebec, Canada 2 IMS Brogan, Kirkland, Quebec, Canada 3 Department of Medicine, Laval University, Quebec City, Quebec, Canada 4 Department of Medicine, Division of Gastroenterology, Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada 5 Applied Health Research Centre, St. Michael’s Hospital, Toronto, Ontario, Canada 6 Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada | ||||
American College of Gastroenterology 2016 Conference, October 14-19, Las Vegas, USA |
||||
, Poster | ||||
, Canada | ||||
Abstract: http://www.imsbrogancapabilities.com/pdf/rwe/abbvie-humira-poster-2016.pdf | ||||
Condition | Year | Language | Analysis type | |
, Gastrointestinal disorders, Medication compliance | 2016 | English | , Database Study | |
Canadian Study of Outcomes in HUMIRA® (Adalimumab) Patients with Support for Adherence - Results from the COMPANION Study | ||||
Gerega S1, Millson B1, Bessette L2, Marshall JK3, Lebovic G4,5, Sung M1, Oraichi D1, Gaetano T6, Gazel S6, Latour M6, Laliberté MC6 | ||||
1 IMS Brogan, Kirkland, Quebec, Canada 2 Department of Medicine, Laval University, Quebec City, Quebec, Canada 3 Department of Medicine, Division of Gastroenterology, Farncombe Family Digestive Health Research Institute; McMaster University, Hamilton, Ontario, Canada 4 Applied Health Research Centre, St. Michael’s Hospital, Toronto, Ontario, Canada 5 Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada 6 AbbVie Corporation, St. Laurent, Quebec, Canada | ||||
American College of Rheumatology 2016 Annual Meeting, November 11-16, Washington DC, USA |
||||
, Poster | ||||
, Canada | ||||
Abstract: http://www.imsbrogancapabilities.com/pdf/rwe/abbvie-acr-poster-2016.pdf | ||||
Condition | Year | Language | Analysis type | |
, Medication compliance, Rheumatology | 2016 | English | , Database Study | |
A quantitative evaluation of the growth in non-physician prescribing in Canada and the resultant impact to key provinces and therapeutic areas | ||||
Shojaie S, Trickett R, Dobson-Belaire WN | ||||
QuintilesIMS, Montreal, Canada | ||||
, Poster | ||||
, Canada | ||||
Abstract: http://www.imsbrogancapabilities.com/pdf/rwe/a-quantitative-evaluation-of-the-growth-in-non-physician.pdf | ||||
Condition | Year | Language | Analysis type | |
, Miscellaneous | 2016 | English | , Retrospective database analysis | |
A Novel Method Using Prescription Treatment Patterns to Estimate Heart Failure Prevalence in Canada | ||||
Jobin Gervais K1, Zaour N1, Caron J2, Borrelli R2, Fischer A2 | ||||
1 Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada 2 IMS Brogan, Mississauga, ON, Canada | ||||
, Poster | ||||
, Canada | ||||
Abstract: http://www.imsbrogancapabilities.com/pdf/rwe/novartis-ispor-poster-2016.pdf | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease | 2016 | English | , Retrospective cohort analysis | |
The Clinical and Economic Impact of Probiotics Consumption on Respiratory Tract Infections: Projections for Canada. | ||||
Lenoir-Wijnkoop I1,2, Gerlier L3, Roy D4, Reid G5 | ||||
1 Utrecht University, Utrecht, The Netherlands 2 Danone Company, Paris, France 3 QuintilesIMS, Zaventem, Belgium 4 Laval University, Quebec, Canada 5 University of Western Ontario, London, Ontario, Canada | ||||
PLoS One., 2016, Nov, 10, 11(11) |
||||
, Abstract | ||||
, Canada | ||||
Abstract: https://www.ncbi.nlm.nih.gov/pubmed/27832195 | ||||
Condition | Year | Language | Analysis type | |
, Respiratory disease | 2016 | English | ||
Pharmaceutical expenditure on drugs for rare diseases in Canada: a historical (2007-13) and prospective (2014-18) MIDAS sales data analysis. | ||||
Divino V1, DeKoven M2, Kleinrock M3, Wade RL2, Kim T4, Kaura S5. | ||||
1 IMS Health, 8280 Willow Oaks Corporate Drive, Suite 775, Fairfax, VA, 22031, USA. vdivino@us.imshealth.com. 2 IMS Health, 8280 Willow Oaks Corporate Drive, Suite 775, Fairfax, VA, 22031, USA. 3 IMS Institute for Healthcare Informatics, One IMS Drive, Plymouth Meeting, PA, 19462, USA. 4 Celgene, 6755 Mississauga Rd, Suite 600, Mississauga, ON, L5N 7Y2, Canada. 5 Celgene, 86 Morris Avenue, H-222H, Summit, NJ, 07901, USA. | ||||
Orphanet J Rare Dis. 2016 May 21;11(1):68 |
||||
, Article | ||||
, Canada | ||||
Abstract: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4875716/ | ||||
Condition | Year | Language | Analysis type | |
, Rare Diseases | 2016 | English | , Budget impact | |
Cost-effectiveness of Radium-223 Dichloride (Radium-223) in Alsympca: A Cost-effectiveness analysis of Radium-223+Best standard of care (BSOC) compared with placebo+BSOC in treatment of Castration-Resistant Prostate Cancer (CRPC) and symptomatic bone metastases in Canada | ||||
Henricks P1, Cislo P2, Zhan L2, Beaudet A3, Grabbi E4, Lloyd A4, Fleshner N5, Chin W6 | ||||
1Bayer Inc, Toronto, ON, Canada, 2Bayer HealthCare, Whippany, NJ, USA, 3IMS Health, Basel, Switzerland, 4IMS Health, London, UK, 5Princess Margaret Hospital, University Health Network, Toronto, ON, Canada, 6ILEX Consulting, Toronto, ON, Canada | ||||
ISPOR 20th Annual International Meeting, Philadelphia, PA, USA, May 16-20 2015 |
||||
, Poster | ||||
, Canada | ||||
Abstract: https://www.ispor.org/research_pdfs/49/pdffiles/PCN74.pdf | ||||
Condition | Year | Language | Analysis type | |
, Oncology | 2015 | English | , Cost effectiveness | |
DISCOVERing treatment of type 2 diabetes in real world settings using electronic medical record databases | ||||
Charbonnel B1, Gomes MB2, Khunti K3, Nicolucci A4, Pocock S5, Shestakova MV6, Shimomura I6, Fenici P7, García-Álvarez L8, Hammar N9, Hashigami K10, Hiller J8, Medina J11, Surmont FA12, Ji L13 | ||||
1University of Nantes, Nantes, France; 2Rio de Janeiro State University, Rio de Janeiro, Brazil; 3University of Leicester, Leicester, UK; 4Center for Outcomes Research and Clinical Epidemiology, Pescara, Italy; 5London School of Hygiene and Tropical Medicine, London, UK; 6Endocrinology Research Center, Moscow, Russian Federation; 7Osaka University, Osaka, Japan; 8AstraZeneca, Cambridge, UK; 9IMS Health, London, UK; 10AstraZeneca, Mölndal, Sweden; 11AstraZeneca, Tokyo, Japan; 12AstraZeneca, Madrid, Spain; 13AstraZeneca, Shanghai, China; 14Diabetes Center, Peking University People’s Hospital, Beijing, China | ||||
EASD - 51st Annual Meeting of the European Association for the Study of Diabetes, 14–18 September 2015, Stockholm, Sweden |
||||
, Poster | ||||
, Canada, France, Germany, UK | ||||
Abstract: http://www.easdvirtualmeeting.org/resources/discovering-treatment-of-type-2-diabetes-in-real-world-settings-using-electronic-medical-record-databases--3 | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2015 | English | , Real World Data, Retrospective database analysis | |
THE COST OF ACUTE CARE HOSPITALIZATIONS ASSOCIATED WITH CHRONIC HEART FAILURE IN CANADA | ||||
Fischer AA1, Liu N1, Borelli R1, Barbeau M2, Zaour N2 | ||||
1IMS Brogan, Mississauga, ON, Canada, 2Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada | ||||
ISPOR 18th Annual European Congress Milan, Italy November, 2015 |
||||
, Poster | ||||
, Canada | ||||
Abstract: http://www.imsbrogancapabilities.com/pdf/rwe/ispor-milan-poster.pdf | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease | 2015 | English | , Cost analysis | |
THE BUDGET IMPACT OF ORPHAN DRUGS IN THE US AND CANADA: A 2007-2013 MIDAS SALES DATA ANALYSIS | ||||
Divino V1, DeKoven M1, Kim T2, Kleinrock M1, Wade RL1, Kaura S3 | ||||
1IMS Health, Fairfax, VA, USA, 2Celgene Corporation, Mississauga, ON, Canada, 3Celgene Corporation, Summit, NJ, USA | ||||
ISPOR 18th Annual European Congress Milan, Italy November, 2015 Value in Health, 2015, 18(7): A666 |
||||
, Poster | ||||
, Canada, USA | ||||
Abstract: https://www.ncbi.nlm.nih.gov/pubmed/26533734 | ||||
Condition | Year | Language | Analysis type | |
2015 | English | , Budget impact | ||
Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study. | ||||
Emery P1, Gottenberg JE2, Rubbert-Roth A3, Sarzi-Puttini P4, Choquette D5, Taboada VM6, Barile-Fabris L7, Moots RJ8, Ostor A9, Andrianakos A10, Gemmen E11, Mpofu C12, Chung C13, Gylvin LH12, Finckh A14. | ||||
1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds, UK NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK. 2Department of Rheumatology, CHU Strasbourg, Strasbourg, France. 3University of Cologne, Cologne, Germany. 4L Sacco University Hospital, Milan, Italy. 5University of Montreal, Montreal, Canada. 6Facultad de Medicina, Hospital Universitario Marqués de Valdecilla, Universidad de Cantabria, Santander, Spain. 7Hospital de Especialidades Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, México City, Mexico. 8Department of Rheumatology, University of Liverpool, Liverpool, UK. 9Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. 10Hellenic Foundation for Rheumatological Research, Athens, Greece. 11Quintiles, Rockville, Maryland, USA. 12F Hoffmann-La Roche Ltd, Basel, Switzerland. 13Genentech Inc, San Francisco, California, USA. 14University Hospital of Geneva, Geneva, Switzerland. | ||||
Ann Rheum Dis. 2015 Jun;74(6):979-84 |
||||
, Article | ||||
, Canada, Colombia, France, Germany, Greece, Italy, Mexico, Norway, Portugal, Spain, UK | ||||
Abstract: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4431330/ | ||||
Condition | Year | Language | Analysis type | |
, Comparative Effectiveness & Health Technology Assessment, Rheumatology | 2015 | English | , Clinical setting: hospital, clinical setting: Secondary care, Prospective study, RWLPR (Real-World Late Phase Research-quintiles | |
Using Electronic Medical Records to Better Understand the Relationship Between Testing, Diagnosis and Treatment of Gonorrhea in Ontario | ||||
Gillman, A | ||||
IMS Brogan, Toronto, Canada | ||||
CAPT Conference 2015 |
||||
, Poster | ||||
, Canada | ||||
Abstract: http://www.imsbrogancapabilities.com/pdf/rwe/capt-2015-conference.pdf | ||||
Condition | Year | Language | Analysis type | |
, Infectious disease | 2015 | English | , Longitudinal study | |
Use of Attention-Deficit/Hyperactivity Disorder Drugs in Canada, 2010-2014 | ||||
Aziz S1, Gillman A2, Griffiths J1 | ||||
1 Marketed Health Products Directorate, Health Canada, Ottawa, ON, Canada 2 IMS Brogan, Toronto, ON, Canada | ||||
ISPOR 2015 |
||||
, Poster | ||||
, Canada | ||||
Abstract: http://www.imsbrogancapabilities.com/pdf/rwe/ispor-2015-use-of-adhd-drugs-in-canada.pdf | ||||
Condition | Year | Language | Analysis type | |
, Mental health | 2015 | English | , Retrospective database analysis | |
The evolving role of real-world evidence to support policy and practice | ||||
Corner N1, Fenwick P2, Brown J3, Husereau D4 | ||||
IMS Health Brogan, Montreal, Canada 2 Alberta Health Services, Alberta, Canada 3 Government Affairs and Market Access, Janssen Inc. 4 Institute of Health Economics | ||||
2015 CADTH Symposium |
||||
, Presentation | ||||
, Canada | ||||
Abstract: http://arc.imshealth.com/gm/document-1.9.7094451/Concurrent%20Session%20E6_Real-World%20Evidence%20to%20Support%20Policy%20and%20Practice_Neil%20Corner.pptx | ||||
Condition | Year | Language | Analysis type | |
2015 | English | |||
The Burden of Gout in the Canadian Primary Care Population | ||||
Williams DM1, Cowan C1, Gendron A1, Goodfield J2, Oraichi D2, Fischer A2, Borrelli R2, Liu N2, Dziarmaga A1 | ||||
1 AstraZeneca Canada Inc., Mississauga, ON, Canada, L4Y 1M4 2 IMS Brogan, A unit of IMS, Mississauga, ON, Canada L5N 6A4 | ||||
ISPOR 2015 |
||||
, Poster | ||||
, Canada | ||||
Abstract: http://www.imsbrogancapabilities.com/pdf/rwe/canadian-burden-of-gout-poster-ispor-may-2015.pdf | ||||
Condition | Year | Language | Analysis type | |
, Miscellaneous | 2015 | English | , Retrospective database analysis | |
Real-World Assessment of Psoriasis Medication Costs Associated With Biologics Treatment in a Canadian Psoriasis Population | ||||
Shear N1, Dobson-Belaire W, Tey G, Goodfield J, Liu FF, Khan Z | ||||
1 University of Toronto, Toronto, ON, Canada 2 IMS Brogan, Mississauga, ON, Canada 3 Celgene Inc., Mississauga, ON, Canada 4 Celgene Corporation, Summit, NJ, USA | ||||
23rd World Congress of Dermatology |
||||
, Poster | ||||
, Canada | ||||
Abstract: http://www.imsbrogancapabilities.com/pdf/rwe/biologic-cost-poster-2015.pdf | ||||
Condition | Year | Language | Analysis type | |
, Dermatology | 2015 | English | , Retrospective database analysis | |
Psoriasis Treatment Progression and Biologic Utilization: A Canadian Retrospective Study | ||||
Shear N1, Dobson-Belaire W2, Tey G2, Reidel K3, Liu FF4, Khan Z5 | ||||
1 Department of Medicine (Dermatology, Clinical Pharmacology), University of Toronto, Toronto, Ontario, Canada and Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada 2 IMS Brogan, a unit of IMS Health, Mississauga, Ontario, Canada 3 IMS Brogan, a unit of IMS Health, Kirkland, Québec, Canada 4 Celgene Inc., Mississauga, Ontario, Canada 5 Celgene Corporation, Summit, NJ, USA | ||||
73rd Annual Meeting of the American Academy of Dermatology |
||||
, Poster | ||||
, Canada | ||||
Abstract: http://www.imsbrogancapabilities.com/pdf/rwe/canadian-drug-claim-database-poster-2015.pdf | ||||
Condition | Year | Language | Analysis type | |
, Dermatology | 2015 | English | , Retrospective database analysis | |
Metastatic Melanoma Patient Characteristics as a Determining Factor for Braf Gene Mutation Testing and Treatment in Canada – a retrospective cohort study | ||||
Djokic S1, Lapierre M2 | ||||
1 IMS Health, Ottawa, ON, Canada 2 IMS Health, Kirkland, QC, Canada | ||||
ISPOR 20th Annual International Meeting |
||||
, Poster | ||||
, Canada | ||||
Abstract: https://www.ispor.org/ScientificPresentationsDatabase/Presentation/55700 | ||||
Condition | Year | Language | Analysis type | |
, Oncology | 2015 | English | , Retrospective cohort analysis | |
Access to New Medicines in Public Drug Plans: Canada and Comparable Countries 2015 Annual Report | ||||
Millson B1, Thiele S1, Zhang Y1, Dobson-Belaire W1, Skinner B2 | ||||
1 IMS Health Canada Inc., 16720 Trans-Canada Highway, Kirkland, Quebec H9H 5M3 2 Innovative Medicines Canada, 55 Metcalfe Street, Suite 1220, Ottawa, Ontario K1P 6L5 | ||||
Innovative Medicines Canada Annual Report 2016 |
||||
, Report | ||||
, Canada | ||||
Abstract: http://innovativemedicines.ca/wp-content/uploads/2016/05/20160524_Access_to_Medicines_Report_EN_Web.pdf | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Health policy | 2015 | English | , Review | |
Evolution of BRAF gene mutation testing and treatment options in BRAF mutation carriers in Canada | ||||
Djokic S | ||||
IMS Brogan, Kanata, ON, Canada | ||||
2015 ASCO Annual Meeting |
||||
, Abstract | ||||
, Canada | ||||
Abstract: http://meetinglibrary.asco.org/content/152450-156 | ||||
Condition | Year | Language | Analysis type | |
, Oncology | 2015 | English | , Retrospective database analysis | |
Dose Pattern Analysis for Biologics in the Treatment of Psoriasis in Canada: Information Retrieved from Administrative Claims Databases | ||||
Gregory V1, Liu N2, Gerega S3, Robertson C2, Barbeau M1 | ||||
1 Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada 2 IMS Health, Mississauga, ON, Canada 3 IMS Health Brogan, Kirkland, QC, Canada | ||||
ISPOR 20th Annual International Meeting |
||||
, Poster | ||||
, Canada | ||||
Abstract: http://www.imsbrogancapabilities.com/pdf/rwe/novartis-IMS-biologics-dose-escalation.pdf | ||||
Condition | Year | Language | Analysis type | |
, Dermatology | 2015 | English | , Longitudinal study, Retrospective cohort analysis | |
Coverage Limits on Blood Glucose Test Strip Reimbursement for Diabetics in Canada: Utilization Impact for Diabetic Patients in the Ontario Public Drug Program (OPDP) | ||||
Bosnic N1, Goodfield J1, Robertson C1, Zhang Y1 | ||||
1 Health Economics and Outcomes Research, IMS Brogan Health, Ontario, Canada | ||||
ISPOR 20th Annual International Meeting, |
||||
, Presentation | ||||
, Canada | ||||
Abstract: http://www.imsbrogancapabilities.com/pdf/rwe/ispor-bosnic-deck-impact-of-diabetes-test-strip-coverage-limits-in-canada.pdf | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2015 | English | , Retrospective database analysis | |
Comparison of Public Reimbursement for Oncology versus Non-oncology Drugs in Canada | ||||
Bosnic N, Donepudi K, Goodfield J, Zhang Y | ||||
1 IMS Brogan, Kanata, ON, Canada 2 IMS Brogan, Mississauga, ON, Canada | ||||
2015 ASCO Annual Meeting |
||||
, Abstract | ||||
, Canada | ||||
Abstract: http://meetinglibrary.asco.org/content/153179-156 | ||||
Condition | Year | Language | Analysis type | |
, Oncology | 2015 | English | , Retrospective database analysis | |
Comparison of patient characteristics and chromosomal abnormalities by first-line treatment in chronic lymphoid leukemia (CLL) patients in Canada | ||||
Marc Lapierre | ||||
IMS Brogan, Kirkland, QC, Canada | ||||
2015 ASCO Annual Meeting |
||||
, Abstract | ||||
, Canada | ||||
Abstract: http://meetinglibrary.asco.org/content/152361-156 | ||||
Condition | Year | Language | Analysis type | |
, Oncology | 2015 | English | , Retrospective cohort analysis | |
Analysis of Etanercept Treatment Patterns and Reimbursement Gaps in Patients Transitioning From Private to Public Drug Plans (poster) | ||||
Millson B1, Poulin-Costello M2, Garces K2 | ||||
1 IMS Health Canada Inc, Kirkland, QC, Canada 2 Amgen Canada, Mississauga, ON, Canada | ||||
ISPOR Annual International Meeting 2015 |
||||
, Poster | ||||
, Canada | ||||
Abstract: http://www.imsbrogancapabilities.com/pdf/rwe/amgen-ppswitch-poster.pdf | ||||
Condition | Year | Language | Analysis type | |
, Medication compliance | 2015 | English | , Retrospective cohort analysis | |
Canadian Retrospective Claim Data Analysis of Biologics Switching and Retention Patterns in Psoriasis Patients (poster) | ||||
Millson B1, Poulin-Costello M2, Garces K2 | ||||
1 IMS Brogan, Kirkland, QC, Canada 2 Amgen Canada Inc., Mississauga, ON, Canada | ||||
ISPOR 20th Annual International Meeting |
||||
, Poster | ||||
, Canada | ||||
Abstract: https://www.ispor.org/ScientificPresentationsDatabase/Presentation/54789 | ||||
Condition | Year | Language | Analysis type | |
, Dermatology, Drug Utlization Study | 2015 | English | , Retrospective database analysis | |
Comparison of Compliance and Discontinuation Rates Among MS Patients Treated with Fingolimod and Other Disease-Modifying Therapies: A Canadian Retrospective Claims Analysis | ||||
Haddad P1, Duquette P2, Yeung M3, Lamarche AM1, Fraelic A4, Chan S4 | ||||
1Novartis Pharmaceuticals Canada Inc., Dorval, Quebec, CANADA 2 Notre Dame Hospital, Université de Montréal, Montreal, Quebec, CANADA 3 University of Calgary, Multiple Sclerosis Clinic, Calgary, Alberta, CANADA 4 IMS Brogan, a unit of IMS Health Canada Inc., Montreal, Quebec, CANADA | ||||
ISPOR Annual European Congress 2015 |
||||
, Poster | ||||
, Canada | ||||
Abstract: http://www.imsbrogancapabilities.com/pdf/rwe/ispor-2015-novartis-patients-poster.pdf | ||||
Condition | Year | Language | Analysis type | |
, Medication compliance | 2015 | English | , Retrospective database analysis | |
Metastatic Melanoma Patient Characteristics as a determining Factor for BRAF Gene Mutation Testing and treatment in Canada. | ||||
Djokic S, Lapierre M | ||||
IMS Health Canada | ||||
IPSOR 2015 Annual Meeting |
||||
, Poster | ||||
, Canada | ||||
Abstract: https://www.ispor.org/research_pdfs/49/pdffiles/PCN137.pdf | ||||
Condition | Year | Language | Analysis type | |
, Oncology | 2015 | English | , Retrospective database analysis | |
Comparison of patient characteristics and chromosomal abnormalities by first-line treatment in chronic lymphoid leukemia (CLL) patients in Canada. | ||||
Lapierre M | ||||
IMS Health Canada | ||||
ASCO 2015 Annual Meeting, 2015, May 29-June 2, Chicago, Illinois, USA |
||||
, Abstract | ||||
, Canada | ||||
Abstract: http://meetinglibrary.asco.org/record/112933/abstract | ||||
Condition | Year | Language | Analysis type | |
, Oncology | 2015 | English | , Retrospective database analysis | |
Evolution of BRAF gene mutation testing and treatment options in BRAF Mutation carriers in Canada. | ||||
Djokic S | ||||
IMS Health Canada | ||||
ASCO 2015 Annual Meeting, 2015, May 29-June 2, Chicago, Illinois, USA |
||||
, Abstract | ||||
, Canada | ||||
Abstract: http://meetinglibrary.asco.org/record/114023/abstract | ||||
Condition | Year | Language | Analysis type | |
, Oncology | 2015 | English | , Observational study, Retrospective cohort analysis | |
Cost-Effectiveness of Rivaroxaban for the Treatment of Pulmonary Embolism in Canada | ||||
Levac B1, Marrie J1, Chin W2, Hassan F3, Bamber L4, McLeod EJ3 | ||||
1Bayer Inc., ON, Canada, 2ILEX Consulting Inc., ON, Canada, 3IMS Health, United Kingdom, 4Bayer Healthcare, Germany | ||||
ISPOR, 19th Annual International Meeting, Montreal, Canada, May 31 - June 4th 2014 - PCV90 Value in Health, 2014, 17(3): A117-A118 |
||||
, Poster | ||||
, Canada | ||||
Abstract: http://www.valueinhealthjournal.com/article/S1098-3015(14)00735-9/abstract | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease | 2014 | English | , Cost effectiveness | |
Validation of a Canadian Primary Care Electronic Medical Record Database | ||||
Dziarmaga A1, Frise S1,3, Tarride JE1,4, Corner N2 | ||||
1 AstraZeneca Canada Inc., Mississauga, ON, Canada 2 IMS Brogan Canada, Kirkland, QC 3 Dalla Lana School of Public Health, University of Toronto 4 Department of Clinical Epidemiology & Biostatistics, McMaster University | ||||
CAPT 2014 Conference |
||||
, Poster | ||||
, Canada | ||||
Abstract: http://www.imsbrogancapabilities.com/pdf/healthcare-capt.pdf | ||||
Condition | Year | Language | Analysis type | |
, Miscellaneous | 2014 | English | , Longitudinal study | |
Using Electronic Medical Records as Real World Evidence to Understand the Impact of Flu Vaccinations on Patient Health | ||||
Gillman A1 | ||||
1 IMS Brogan, Toronto, Canada | ||||
CAPT 2014 |
||||
, Poster | ||||
, Canada | ||||
Abstract: http://www.imsbrogancapabilities.com/pdf/rwe/capt2014-conference-poster-final-corrected.pdf | ||||
Condition | Year | Language | Analysis type | |
, Diabetes, Infectious disease | 2014 | English | , Longitudinal study | |
Understanding Treatment Patterns of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Proton Pump Inhibitors (PPIs) in Patients with the Signs and Symptoms of Osteoarthritis (OA), Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS) | ||||
Dziarmaga A1, Reide Kl2, White R1, Tarride J1, Corner N2 | ||||
1 A straZeneca 2 IMS Brogan Canada (A Unit of IMS Health) | ||||
ISPOR 2014 |
||||
, Poster | ||||
, Canada | ||||
Abstract: http://www.imsbrogancapabilities.com/pdf/rwe/nsaids-ispor-banner-2014-print.pdf | ||||
Condition | Year | Language | Analysis type | |
, Rheumatology | 2014 | English | , Longitudinal study | |
Reimbursement Patterns for Enbrel® (etanercept) As Senior Patients Transition From Private to Public Drug Plan Insurance | ||||
Garces K1 , Poulin-Costello M1, Millson B2 | ||||
1 Amgen Canada, Mississauga, ON, Canada 2 IMS Health Canada Inc, Kirkland, QC, Canada | ||||
CAPT 2014 |
||||
, Poster | ||||
, Canada | ||||
Abstract: http://www.imsbrogancapabilities.com/pdf/rwe/amgencapt-poster-print.pdf | ||||
Condition | Year | Language | Analysis type | |
, Pricing and reimbursement | 2014 | English | , Retrospective cohort analysis | |
Impact of the Pan-Canadian Pricing Alliance Initiative on Time to Listing in Canada: An Analysis of Pharmaceutical Coverage | ||||
Robertson C, Zhang Y, Bosnic N | ||||
IMS Brogan, Canada | ||||
, Poster | ||||
, Canada | ||||
Abstract: http://www.imsbrogancapabilities.com/pdf/rwe/impact-of-the-pan-canadian-pricing-alliance.pdf | ||||
Condition | Year | Language | Analysis type | |
, Miscellaneous | 2014 | English | , Retrospective database analysis | |
Identifying Psoriasis and Psoriatic Arthritis Patients in Retrospective Databases When a Diagnosis Code Is Not Available: A Validation Study Comparing Medication/Prescriber Visit Based Algorithms to Diagnosis Codes | ||||
Dobson-Belaire W1, Goodfield J1, Borrelli R1, Liu F2, Khan Z3 | ||||
1 IMS Brogan, a unit of IMS Health, Mississauga, ON, Canada 2 Celgene Inc., Mississauga, ON, Canada 3 Celgene Corporation, Summit, NJ, USA | ||||
ISPOR 2014 |
||||
, Poster | ||||
, Canada | ||||
Abstract: https://www.ispor.org/research_pdfs/48/pdffiles/PRM214.pdf | ||||
Condition | Year | Language | Analysis type | |
, Dermatology | 2014 | English | , Retrospective database analysis | |
Diabetes complexities drive resource consumption in Canada | ||||
Borrelli R, Mokin S, Sung M | ||||
IMS Brogan | ||||
Accesspoint, 2014, 5(9): 15-19 |
||||
, Article | ||||
, Canada | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2014 | English | , Retrospective database analysis | |
Assessment of a Canadian Primary Care Electronic Medical Record Database for Use in Observational Studies | ||||
Frise S1,3, Reidel K2, Tarride JE1,4, Corner N2, Dziarmaga A1 | ||||
1 AstraZeneca Canada Inc., Mississauga, ON, Canada 2 IMS Brogan Canada, Kirkland, QC 3 Dalla Lana School of Public Health, University of Toronto 4 Department of Clinical Epidemiology & Biostatistics, McMaster University | ||||
, Poster | ||||
, Canada | ||||
Abstract: http://www.imsbrogancapabilities.com/pdf/rwe/assessment-of-a-primary-care-database.pdf | ||||
Condition | Year | Language | Analysis type | |
, Miscellaneous | 2014 | English | , Observational study | |
Mortality trends in patients with and without diabetes in Ontario, Canada and the UK from 1996 to 2009: a population-based study | ||||
Lind M1, Garcia-Rodriguez LA, Booth GL, Cea-Soriano L, Shah BR, Ekeroth G & Lipscombe LL | ||||
1 Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg Institute of Medicine Department of Molecular and Clinical Medicine | ||||
Diabetologia. 2013 Dec;56(12):2765. doi: 10.1007/s00125-013-2949-2. Epub 2013 Jun 22 |
||||
, Article | ||||
, Canada, UK | ||||
Abstract: https://www.ncbi.nlm.nih.gov/pubmed/24114114 | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2013 | English | , Retrospective database analysis | |
ASSESSMENT OF A CANADIAN PRIMARY CARE ELECTRONIC MEDICAL RECORD DATABASE FOR USE IN OBSERVATIONAL STUDIES | ||||
Frise S1, Reidel K2, Tarride JE1, Corner N2, Dziarmaga A1 | ||||
1 AstraZeneca Canada Inc., Mississauga, ON, Canada, 2 IMS Brogan Canada, Kirkland, QC, Canada | ||||
ISPOR 16th Annual European Congress, Dublin,November, 2013 Value in Health, 2013, 16(7): A582 |
||||
, Poster | ||||
, Canada | ||||
Abstract: http://www.valueinhealthjournal.com/article/S1098-3015(13)03503-1/abstract | ||||
Condition | Year | Language | Analysis type | |
, Database Validity and methodology | 2013 | English | , Retrospective database analysis | |
Using Anonymized Longitudinal Patient Data to Monitor the Impact of Reimbursement Policies on Patient Compliance | ||||
Gillman, A | ||||
IMS Brogan, Toronto, Canada | ||||
CAPT 2013 |
||||
, Poster | ||||
, Canada | ||||
Abstract: http://www.imsbrogancapabilities.com/pdf/rwe/capt-agillman-final.pdf | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2013 | English | , Longitudinal study | |
Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: A Canadian analysis using the Ontario Ministry of Health Perspective | ||||
McDonald H1, Diamantopoulos A2, Wells P3, Lees M4, Folkerts K5, Forster F6, Ananthapavan J6 | ||||
1 Bayer Inc., Toronto, Canada 2 Symmetron Limited, London, UK 3 Department of Medicine, Ottawa Hospital and University of Ottawa, Canada 4 Bayer plc, Uxbridge, UK 5 Bayer Pharma AG, Wuppertal, Germany 6 IMS Health, London, UK | ||||
Journal of Medical Economics Vol. 15, No. 5, 2012, 1–12 |
||||
, Article | ||||
, Canada | ||||
Abstract: https://www.ncbi.nlm.nih.gov/pubmed/22494267 | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease | 2012 | English | , Cost effectiveness | |
Cost of self-monitoring of blood glucose in Canada among patients on an insulin regimen for diabetes | ||||
Yeaw J1, Lee WC1, Wolden ML2, Christensen T2, Groleau D2 | ||||
1 IMS Health, Redwood City, CA, US 2 Novo Nordisk, Copenhagen, Denmark | ||||
Diabetes Ther. 2012 Nov;3(1):7. Epub 2012 Jun 27. |
||||
, Article | ||||
, Canada | ||||
Abstract: https://www.ncbi.nlm.nih.gov/pubmed/22736405 | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2012 | English | , Retrospective cohort analysis | |
Development and validation of the self-completed ascites impact measure to understand patient motivation for requesting a paracentesis. | ||||
Crawford B1, Piaut E2, Gotlieb W3, Joulain F4 | ||||
1 Mapi Values, Tokyo, Japan 2 2Mapi Values, Boston, MA, USA 3 McGill University, Montreal, Quebec, Canada 4Sanofi, Paris, France | ||||
Patient Relat Outcome Meas. 2012 Jul; 3: 21–30. Published online 2012 Jun 21. doi: 10.2147/PROM.S28179 |
||||
, Article | ||||
, Canada, USA | ||||
Abstract: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3417936/ | ||||
Condition | Year | Language | Analysis type | |
, Gastrointestinal disorders | 2012 | English | , Patient questionnaire | |
Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence. | ||||
Johnson JA1, Carstensen B2 3, Witte D2, Bowker SL1, Lipscombe L4 & Renehan AG5 | ||||
1 School of Public Health, University of Alberta, 2 Steno Diabetes Center, 3 2 Department of Biostatistics, University of Copenhagen 4 Women’s College Hospital, University of Toronto, 5 School of Cancer and Enabling Sciences, University of Manchester | ||||
Diabetologia. 2012 Jun;55(6):1607-18. doi: 10.1007/s00125-012-2525-1. Epub 2012 Apr 4. |
||||
, Article | ||||
, Canada, UK | ||||
Abstract: http://link.springer.com/article/10.1007/s00125-012-2525-1/fulltext.html | ||||
Condition | Year | Language | Analysis type | |
, Diabetes, Oncology | 2012 | English | , Retrospective cohort analysis, Retrospective database analysis | |
Canada’s pharmaceutical industry and prospects | ||||
IMS Brogan | ||||
IMS Brogan, Industry Canada | ||||
Industry Canada, Government of Canada |
||||
, Report | ||||
, Canada | ||||
Abstract: https://www.ic.gc.ca/eic/site/lsg-pdsv.nsf/eng/hn01768.html | ||||
Condition | Year | Language | Analysis type | |
2012 | English | , Review | ||
Modeling the lifetime costs of insulin glargine and insulin detemir in type 1 and type 2 diabetes patients in Canada: a meta-analysis and a cost-minimization analysis | ||||
Guillermin A1, Samyshkin Y1, Wright D1, Nguyen T1, Villeneuve J2 | ||||
1 IMS Health, London, UK 2 Sanofi-Aventis, Laval, Canada | ||||
Journal of Medical Economics 2011; 14(2):207-216 |
||||
, Article | ||||
, Canada | ||||
Abstract: https://www.ncbi.nlm.nih.gov/pubmed/21361858 | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2011 | English | , Cost minimization, Meta analysis | |
PDB78 Randomized clinical trial (RCT) design and analytic issues impacting assumed clinical effects and results of cost-effectiveness analyses: Illustration from a recent Canadian report on the cost-effectiveness of blood glucose test strips for type 2 diabetes. | ||||
Tunis S | ||||
IMS Health Inc., Falls Church, VA, USA | ||||
ISPOR 15th Annual International Meeting, May 15-19, 2010, Atlanta, GA, USA Value in Health, 2010, 13(3): A68 |
||||
, Poster | ||||
, Canada | ||||
Abstract: http://www.valueinhealthjournal.com/article/S1098-3015(10)72320-2/abstract | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2010 | English | , Cost effectiveness | |
Systemic lupus erythematosus (SLE) is costly for the Health care system and workplace: a systematic literature review | ||||
Doria A1, Grandfils N2, Maurel F2, Rudge H3 | ||||
1 University of Padova, Padova, Italy 2 IMS Health, Paris, France 3 GlaxoSmithKline, Uxbridge, UK | ||||
ISPOR 13th Annula European Congress to be held 6-9 November 2010 at the Prague Congress Centre in Prague, Czech Republic |
||||
, Abstract, Poster | ||||
, Canada, Germany, UK, USA | ||||
Condition | Year | Language | Analysis type | |
, Dermatology | 2010 | English | , Literature Review | |
The Economic Impact of Overactive Bladder Syndrome in Six Western Countries. | ||||
Irwin DE1, Mungapen L2, Milsom I3, Kopp Z4, Reeves P2, Kelleher C5 | ||||
1Department of Epidemiology, School of Public Health, University of North Carolina, Chapel Hill, NC, US 2 IMS Health incorporating Fourth Hurdle Consulting Ltd, London, UK 3 Department of Obstetrics & Gynaecology, Sahlgrenska Academy at the University of Gothenburg, Sweden 4 Pfizer Inc., New York, USA, , 5 Department of Obstetrics and Gynaecology, Guy’s and St Thomas’ NHS Foundation Trust, London, UK | ||||
British Journal of Urology International (BJU International), 103(2):202-209 |
||||
, Article | ||||
, Canada, Germany, Italy, Spain, Sweden, UK | ||||
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/19278532?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=1 | ||||
Condition | Year | Language | Analysis type | |
, Overactive bladder | 2009 | English | , Budget impact | |
Health economic comparison between continuous subcutaneous insulin infusion (CSII) and multiple daily injections (MDI) of insulin for the treatment of adult type 1 diabetes in Canada. | ||||
St. Charles M1, Sadri H2, Minshall M1, Tunis S3 | ||||
1 Formerly of IMS Health, Indianapolis, IN, US 2 Medtronic Canada Ontario 3 IMS Health, Indianapolis, IN, US | ||||
Clinical Therapeutics, 2009, 31(3): 657-67 |
||||
, Manuscript in preparation | ||||
, Canada | ||||
Abstract: http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6VRS-4W4CMKG-N&_user=10&_rdoc=1&_fmt=&_orig=search&_sort=d&_docanchor=&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=bbc2be5b77a418d332505b1ea4e93261 | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2009 | English | , Cost effectiveness | |
Cost-effectiveness of insulin analogues for diabetes mellitus | ||||
Cameron C1, Bennett H1 | ||||
1 Canadian Agency for Drugs and Technologies in Health, Ottawa, Canada | ||||
Canadian Medical Association Journal, 2009, 180(4): 400-407 |
||||
, Article | ||||
, Canada | ||||
Abstract: http://www.cmaj.ca/cgi/content/full/180/4/400 | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2009 | English | , Cost effectiveness | |
A Globally Optimal k-Anonymity Method for the De-identification of Health Data. | ||||
KHALED EL EMAM, PHD, FIDA KAMAL DANKAR, PHD, ROMEO ISSA, MS, ELIZABETH JONKER, BA, DANIEL AMYOT, PHD, ELISE COGO, ND, JEAN-PIERRE CORRIVEAU, PHD, MARK WALKER, MS, MD, SADRUL CHOWDHURY, MS, REGIS VAILLANCOURT, BPHARM, PHARMD, TYSON ROFFEY, BA, JIM BOTTOMLEY, BSCH, MHA | ||||
Children’s Hospital of Eastern Ontario Research Institute (KEE, FKD, EJ, EC, RV, TR, JB), Ottawa, Ontario, Canada; Pediatrics, Faculty of Medicine (KEE), School of Information Technology and Engineering (DA, SC), University of Ottawa, Ottawa, Ontario, Canada; School of Computer Science (RI, J-PC), Carleton University, Ottawa, Ontario, Canada; Ottawa Hospital Research Institute (MW), Ottawa, Ontario, Canada. | ||||
Journal of the American Medical Informatics Association |
||||
, Article | ||||
, Canada | ||||
Abstract: https://watermark.silverchair.com/jamia.m3144.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAh8wggIbBgkqhkiG9w0BBwagggIMMIICCAIBADCCAgEGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMV_JYq2YeyT3x7ZGGAgEQgIIB0m8zmdADRJniIyvyVCYC8USRD7o4BkEOoK4uF65LmDb24pXAbafplEsE8JYZFNlsfioGMd3VElD1BCSdQiMP3whzpkqiJKOY9QBvdmwATCq79TkYj0mYawUN3N7_8FJeJcBSX2QBw93JwWk3qsBmtdcrBx7JuUeIvEiqfKP_T_U5_7V61pveujmYMOG-7oaa5q3plG1aj_DIzsj84UOdvL_Tr1rsv0zOOJoSTtsUuDVz7vXHuIFhhXhgtzRkZ2BDJYU1dN9bjIumrVJLcEkVEJRyJqGL5arzFn5CyHnUMPwuU4xNMok8JS_fdYrJhRz_POHRHHITCk9lqy6xtfIZV8Q1X8LhlO3QAHgyl6yX3wkktjGEfB7KHop1heWnTV5jFo95UFO4s1CtN_CmhDQxv_I139JdablwNc8BCCqNVXgDGcix1HOFWccp1LWxnLO_D2loe7bZgb_oPeHxmazvNH_PP8PK_2NlfxRQ98FXGryUlm7A-Otjg_HZJb_2bMlEI07sLnI1n9x9YOHJT5ZqMTbgfROrqs8J7dxSG0j7GLoOB04_4tBWmBRhWP1HOwROwFuJDW9chF5spZfkEu0w26WV9UxFN0LssqYFhhrxgTXZWnQ | ||||
Condition | Year | Language | Analysis type | |
, Methodology | 2009 | English | , De-identification / anonymisation | |
Canadian cost utility analysis comparing exenatide versus insulin glargine in patients with type two diabetes | ||||
Coyle D, Coyle K, Valentine WJ, Lee JB, Kisswani R, Boye KS | ||||
ISPOR 2008 13th Annual International Congress |
||||
, Poster | ||||
, Canada | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2008 | English | , Cost utility | |
Gadofosveset in the management of peripheral arterial occlusive disease in Canada - a model approach focusing on diagnostic confidence | ||||
Hass B1, Rebeira M2, Lungershausen J1, Jaszewski B2, D`Onofrio F2, Kienbaum S3 | ||||
1 IMS Health, Nuremberg, Germany 2 Bayer HealthCare, Toronto, ON, Canada 3 Bayer Schering Pharma AG, Berlin, Germany | ||||
ISPOR 13th Annual International Congress, May 3-7, 2008, Toronto, Canada ISPOR 13th Annual International Congress, May 3-7, 2008,Toronto, Canada Value in Health, 2008, 11(3): A196 |
||||
, Abstract, Oral presentation, Poster | ||||
, Canada | ||||
Abstract: http://www.valueinhealthjournal.com/article/S1098-3015(10)70623-9/abstract | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease, Vascular disease | 2008 | English | , Cost benefit, Cost effectiveness | |
The cost-utility of aliskiren in the treatment of mild to moderate hypertension. A Canadian health care system perspective | ||||
Lee A, Barry SJ, Leiter L, Nanji A, Annemans L, Tucker D, Michaliszyn AF, Barbeau M, Vincze G | ||||
ISPOR 13th Annual International Meeting, 2008, May 3-7, Toronto, Canada |
||||
, Poster | ||||
, Canada | ||||
Abstract: http://www.valueinhealthjournal.com/article/S1098-3015(10)70642-2/abstract | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease | 2008 | English | , Cost utility | |
Cost-Effectiveness of Insulin Detemir Compared to NPH Insulin for Type 1 (T1DM) and Type 2 Diabetes Mellitus (T2DM) in the Canadian Payer Setting: modeling analysis | ||||
Tunis S1, Minshall M2, Conner C, McCormick J, Kapor J, Yale J, Groleau D | ||||
1 IMS Health, Falls Church, VA, US 2 Formerly of IMS Health, Falls Church, VA, US | ||||
Current Medical Research and Opinion, 2009, 25(5): 1273-84 |
||||
, Manuscript in preparation, Poster | ||||
, Canada | ||||
Abstract: https://www.ncbi.nlm.nih.gov/pubmed/19366302 | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2008 | English | , Cost effectiveness | |
Cost-effectiveness of Insulin Detemir Compared to NPH Insulin for Type 1 Diabetes mellitus (T1DM) in the Canadian Payer Setting: Modeling Analysis using a Randomized Controlled Trial. | ||||
Minshall ME1, Tunis SL2, Conner C, McCormick JI, Kapor J, Groleau D | ||||
1 Formerly of IMS Health, Falls Church, VA, USA IMS Health, Falls Church, VA, USA | ||||
ISPOR 2008 13th Annual International Congress Value in Health, 2008; 11(3):A223-A224. |
||||
, Manuscript in preparation, Poster | ||||
, Canada | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2008 | English | , Cost effectiveness | |
Cost-Effectiveness of Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Hip Replacement in Canada | ||||
Diamantopoulos A1, Forster F1, Lees M2, McDonald HP3 | ||||
1 IMS Health, London, UK, 2 Bayer HealthCare, Uxbridge, UK, 3 Bayer Inc, Toronto, ON, Canada | ||||
ISPOR 11th Annual European Congress 2008 November 8-11, Athens, Greece Thrombosis and haemostasis, 2010, 104(4): 760-70 |
||||
, Poster | ||||
, Canada | ||||
Abstract: https://www.ncbi.nlm.nih.gov/pubmed/20806107 | ||||
Condition | Year | Language | Analysis type | |
, Musculoskeletal disease | 2008 | English | , Cost effectiveness | |
Prevalence of opioid dispensings and concurrent gastrointestinal medications in Quebec | ||||
Williams RE1, Bosnic N2, Sweeney CT3, Duncan AW3, Levine KB4, Brogan M2, Cook SF3 | ||||
1 Worldwide Epidemiology, GlaxoSmithKline, Collegeville, Pennsylvania, USA 2 Brogan Inc, Ottawa, Ontario 3 Worldwide Epidemiology, GlaxoSmithKline, Research Triangle Park 4 Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA | ||||
Pain Research & Management, 2008, 13(5): 395–400. |
||||
, Abstract | ||||
, Canada | ||||
Abstract: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2799263/ | ||||
Condition | Year | Language | Analysis type | |
, Gastrointestinal disorders, Pain | 2008 | English | , Retrospective cohort analysis | |
Prevalence of opioid dispensings and concurrent gastrointestinal medications in an elderly population from Ontario, Canada | ||||
Williams R1, Bosnic N, Duncan AW, Brogan M, Cook SF | ||||
1 GlaxoSmithKline, Worldwide Epidemiology, Research Triangle Park, North Carolina, USA | ||||
Journal of Opioid Management, 2008, 4(4): 193-200 |
||||
, Abstract | ||||
, Canada | ||||
Abstract: https://www.ncbi.nlm.nih.gov/pubmed/18837202 | ||||
Condition | Year | Language | Analysis type | |
, Gastrointestinal disorders, Pain | 2008 | English | , Retrospective cohort analysis | |
Cost-Effectiveness of Insulin Detemir Compared to NPH Insulin for Type 2 Diabetes Mellitus (T2DM) in the Canadian Payer Setting: Modeling Analysis using an Observational Study | ||||
Minshall ME1, Tunis SL2, Conner C, McCormick JI, Kapor J, Groleau D | ||||
1 Formerly of IMS Health, Falls Church, VA, USA IMS Health, Falls Church, VA, USA | ||||
ISPOR 2008 13th Annual International Congress |
||||
, Poster | ||||
, Canada | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2008 | English | , Observational study | |
SMBG Cost-Effectiveness in Canada | ||||
Minshall M1, Tunis SL2, Tuttle, J, Ur E | ||||
1 Formerly of IMS Health, Falls Church, VA, US 2 IMS Health, Falls Church, VA, US | ||||
Canadian Diabetes Association Professional Conference, Vancouver, October 24-27, 2007 |
||||
, Abstract | ||||
, Canada | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2007 | English | , Cost effectiveness | |
Cost-utility analysis of rituximab as a new therapeutic option for rheumatoid arthritis patients in Canada | ||||
Mistry B1, McCormick J2, Diamantopoulos A3, Kielhorn A4 | ||||
1 Hoffmann-La Roche Ltd, Mississauga, ON, Canada, 2McKesson Phase 4 Solutions, Toronto, ON, Canada, 3M-TAG UK Ltd, London, UK, 4F. Hoffmann-La Roche Ltd, Basel, Switzerland | ||||
ISPOR 9th Annual European Congress. Copenhagen, Denmark Value in Health, 2006, 9(6): A222 |
||||
, Abstract, Poster | ||||
, Canada | ||||
Abstract: http://www.valueinhealthjournal.com/article/S1098-3015(10)63265-2/abstract | ||||
Condition | Year | Language | Analysis type | |
, Rheumatology | 2006 | English | , Cost utility | |